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POTASSIUM CHANNELOPATHIES IN PULMONARY ARTERIAL HYPERTENSION 
 
 
Michael S. Bohnen 
 
 
A debilitating illness, pulmonary arterial hypertension (PAH) arises from deleterious remodeling 
of pulmonary arterioles, leading to increased pulmonary artery pressure, a rise in pulmonary 
vascular resistance, right sided heart failure and death. The pathogenesis of the disease is 
incompletely understood; however, certain established pathological features have guided medical 
treatments to improve mortality rates. For instance, an imbalance of vasoconstrictor molecules, 
such as endothelin-1, to vasodilator compounds, such as nitric oxide, contributes to excessive 
pulmonary arterial constriction, and a propensity for pulmonary arterial smooth muscle and 
endothelial cell proliferation. Therapeutic strategies may aim to restore this imbalance with the use 
of endothelin receptor antagonists, prostacyclin analogs, and other vasodilating agents.  
 
Mutations in the BMPR2 gene, the most common genetic cause of PAH, leads to aberrant TGF-ß 
signaling, which promotes uncontrollable cell proliferation and pathological changes in pulmonary 
arterioles. Genetic studies have revealed PAH-associated mutations in several other genes within 
the TGF-ß signaling pathway. More recently, our research group discovered loss-of-function 
mutations in the KCNK3 gene encoding the KCNK3 two-pore domain potassium channel in 
patients with idiopathic and familial PAH.  
 
KCNK3 (also referred to as TASK-1, or K2P3.1) represents the first ion channelopathy as a cause 
of PAH. KCNK3 is expressed in human pulmonary artery smooth muscle and endothelial cells. 
Loss of KCNK3 channel currents leads to membrane depolarization and predisposes to deleterious 
pulmonary arterial remodeling. Chapter 1 of my thesis explores the impact of KCNK3 mutations 
on potassium channel function in cellular models of heterozygous conditions, as all patients with 
PAH-associated KCNK3 mutations in our study were heterozygous at the KCNK3 gene locus. 
 
Furthermore, we explored function of mutant and non-mutant KCNK3 channels in cultured human 
pulmonary artery smooth muscle cells to better define the electrophysiological consequence of 
KCNK3 dysfunction, and used a KCNK3-activating pharmacological agent, ONO-RS-082, to 
gauge the therapeutic potential of KCNK3 as a pharmacological target in PAH. Moreover, the 
study of KCNK3 channel activity when assembled with the closely related KCNK9 channel 
provided a platform for exploring the lung-specific phenotype in patients with heterozygous 
KCNK3 mutations, despite widespread tissue expression KCNK3 in the body. 
 
In Chapter 2 of my thesis work, the discovery of a second potassium channelopathy in PAH is 
characterized. Heterozygous mutations in the ABCC8 gene, encoding the sulfonylurea receptor 1 
(SUR1) protein, were found in pediatric and adult patients with idiopathic and familial PAH. 
SUR1, a beta subunit of the ATP-sensitive potassium channel (KATP), assembles with the pore-
forming Kir6.2 alpha subunit to form KATP, a channel sensitive to inhibition by intracellular ATP. 
At the plasma membrane, KATP inwardly rectifying potassium currents contribute to the resting 
potential, and may play a pathophysiological role in PAH via dysfunction in pulmonary artery 
smooth muscle and/or endothelial cells. In this chapter, eight ABCC8 mutations associated with 
PAH were functionally characterized, and pharmacological agents were employed to examine the 
therapeutic potential in targeting SUR1-containing KATP channels in PAH. 
 Altogether, the research presented in this dissertation identifies and explores potassium channel 
dysfunction as a pathogenic mechanism in PAH, due to heterozygous genetic mutations in KCNK3 
and ABCC8. Evidence of restoration of mutant KCNK3 and KATP channel function by 
pharmacological agents suggests that targeting potassium channels as a therapeutic strategy may 
alleviate the severe morbidity and mortality burden in patients with PAH. 
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Epidemiology of PAH   
 
Pulmonary arterial hypertension (PAH) is defined as a “pre-capillary” cause of pulmonary 
hypertension, in patients with a mean pulmonary arterial pressure ³ 25 mmHg, and a PAWP £ 15 
mmHg.5 Group 1 pulmonary arterial hypertension according to World Health Organization 
classification, may be further subdivided into the following four clinical sub-classifications:5 
 
1.1) Idiopathic 
1.2) Heritable (due to known genetic mutations) 
1.3) Drug and toxin induced (eg. Fenfluramine, Aminorex)  
1.4) Associated (ie. associated with connective tissue disease, HIV infection, portal 
hypertension, congenital heart disease, or schistosomiasis infection) 
 
A rare disease, the prevalence of PAH is approximately 5-60 cases per million adults, and the 
incidence of PAH approximately 2-10 cases per million individuals per year.6-8 About half of PAH 
patients carry an Idiopathic (IPAH), Heritable (HPAH), or Drug-induced diagnosis. IPAH patients 
have no known family history of the disease, and no known genetic cause of the illness. In current 
patient registries, IPAH patients carry a mean age at diagnosis of 50 to 65 years, however this may 
be in part attributable to the age characteristics of the patient cohorts under study.5 
 
Pulmonary hypertension due to any cause carries an approximate prevalence reported in the UK 
of 1 case per 10,000, with a 1.8 female to male ratio. Left heart disease is thought to be the most 
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common cause of pulmonary hypertension in general, although this has not been established 
through comparative epidemiological studies.5 On a global scale, high altitude-related and 
schistosomiasis-associated PAH have major, deleterious impacts in specific regions worldwide.5  
 
Genetics of PAH 
 
The first HPAH susceptibility locus, PPH1, was mapped to chromosome 2q31-32 by two research 
groups.9,10 Following this discovery, bone morphogenetic protein receptor II (BMPR2) was 
identified as the gene within the PPHI locus associated with HPAH.11,12 In PAH, BMPR2 
mutations exist in approximately 70% of cases of familial PAH (FPAH), and in 10-40% of 
idiopathic PAH cases.13-16 Additional rare causes of PAH within the TGF-ß signaling pathway 
include mutations in BMPR1B, SMAD3, SMAD8, SMAD9, endoglin (ENG), and activin receptor-
like kinase 1 (ALK-1).17 Furthermore, mutations in CAV1, which regulates SMAD2/3 
phosphorylation, is associated with PAH; and more recently, mutations in KCNK3, a two-pore 
domain potassium channel, were identified in FPAH and IPAH patients.3 Whole exome 
sequencing was used to identify mutations in CAV1 and KCNK3 as rare causes of PAH in 
heterozygous patients.3,17 In addition to inherited and de novo mutations in the above-mentioned 
PAH-associated genes, single-nucleotide polymorphisms, including in transporter and ion channel 
genes, can predispose to PAH.18  
 
Nearly all hereditary cases of PAH arise from autosomal dominant transmission of disease-causing 
mutations. While accounting for most cases of FPAH, BMPR2 mutations harbor low penetrance, 
with an estimated risk of developing PAH set at 20 percent.16,19 Incomplete penetrance and 
heterogeneous genetics underscore the complex pathogenetic basis for PAH in many patients. For 
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instance, heterozygous germline ALK1 and ENG mutations cause hereditary hemorrhagic 
telangiectasia (HHT),20,21 and rarely cause PAH. 
  
Pathophysiological basis of PAH 
 
At the pulmonary arterial level in PAH patient lungs, an excess of vasoconstriction, proliferation, 
and thrombosis predominate in the setting of endothelial dysfunction. Patients with IPAH produce 
reduced amounts of nitric oxide (NO) from pulmonary artery endothelial cells (PAECs). NO is a 
potent vasodilator of pulmonary arteries, and aids in the suppression of pulmonary artery smooth 
muscle cell (PASMC) proliferation.22,23 Moreover, endothelin-1 levels are elevated, promoting 
pulmonary arterial vasoconstriction and deleterious remodeling.  
 
Treatment options such as endothelin-receptor antagonists, thromboxane inhibitors, nitric oxide, 
and prostacyclin analogs aim to restore the imbalance of vasoconstrictive versus vasodilatory 
mediators (Figure I1).18 Potassium channel dysfunction (as described in detail below) may occur 
up- or downstream of these pathways to further exacerbate pulmonary vascular cell proliferation 
and constriction. 
 
In children and adults, intimal hyperplasia may lead to vessel occlusion and plexiform lesions 
within distal pulmonary arteries.22 PAEC proliferation predisposes to plexiform lesions. PAECs 
display increased Tie2 receptor expression in patients with IPAH, leading to serotonin release and 
excessive PASMC proliferation.24  Enhanced PASMC proliferation also occurs via increased 
growth factor signaling, and/or a failure in apoptotic and growth suppressor cell signaling.25-27 The 
muscularization of distal pulmonary arterioles in close proximity to the alveolar wall and ducts is 
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thought to occur in the setting of pericyte differentiation into smooth muscle cells.22 Ultimately, 
pathological changes in pulmonary arteries lead to a rise in pulmonary artery pressure, increased 
pulmonary vascular resistance, and right-sided heart failure. 
 
Smooth muscle cells may be classified based on their predominant phenotype: contractile versus 
proliferative. Contractile SMCs are considered more highly differentiated, while proliferative 
Figure I1. Pathogenic mechanisms guide treatment in pulmonary arterial hypertension. 
Three signaling pathway molecules involved in PAH pathogenesis -- endothelin-1, nitric oxide, 
and prostacyclin -- are targeted therapeutically in patients. Reproduced with permission from 2, 
Copyright Massachusetts Medical Society.  
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SMCs are less differentiated (or “dedifferentiated” if they were previously in the more 
differentiated contractile state). In pulmonary hypertension, a relatively high proportion of SMCs 
exist in the proliferative SMC state,28 which promotes deleterious pulmonary arterial remodeling.  
Changes in potassium channel and other channel expression patterns contribute to the 
transformation from the contractile to proliferative SMC phenotype;29-31 in cultured PASMCs, 
downregulation of expressed potassium channels leads to cell depolarization and a predominance 
of the proliferative SMC phenotype.32 In a related phenomenon, K+ efflux from PASMCs aids in 
the concerted apoptotic intracellular cascades, and PASMCs in PAH patients exhibit resistance to 
apoptosis, in part due to decreased K+ channel expression.33  
 
At the cellular and molecular level, imbalances in the TGF-ß signaling pathway contribute greatly 
to altered PASMC and PAEC proliferation, apoptosis, and differentiation, and impacts 
extracellular matrix secretion and accumulation. Enhanced expression of TGF-ß and 
glycosaminoglycans occurs, in addition to increased expression of matrix proteins such as 
tenascin-C and fibronectin.34 Inflammatory cells (B and T cells, macrophages) may invade 
pulmonary arteries,22,35 and increased expression of modulators of inflammation, such as 
S100A4/Mts1 and fractalkine, has been observed.36,37 Mutations in BMPR2 -- or in other TGF-ß 
pathway genes associated with PAH -- lead to dysregulation of the TGF-ß pathway, increasing the 
cell proliferation/apoptosis ratio. Furthermore, excessive glycolytic (anaerobic) metabolism and 
impaired mitochondrial functioning may occur in PASMCs, PAECs, and fibroblasts. The 
excessive cell growth, impaired apoptosis, and altered cell metabolism in PAH resembles the 
pathogenesis of cancer.18 
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Certain experimental therapeutic approaches are aimed at alleviating PAH by restoring the 
proliferation/apoptosis and metabolic balances. Such experimental therapies include pyruvate 
dehydrogenase kinase inhibitors that would alter metabolic processes; tyrosine kinase inhibitors, 
rho kinase inhibitors, and inhibitors of transcription factors such as hypoxia-inducible factor [HIF]-
1a and nuclear factor of activated T lymphocytes [NFAT], involved in regulating responses to 
hypoxia and inflammation, respectively.18 Furthermore, BMPR2 signaling enhancers and 
potassium channel activators may restore proper cell growth balance.18 Interestingly, epigenetic 
changes in superoxide dismutase 2 may predispose to the development of PAH in individuals 
possessing a known pathogenic PAH mutation, and therefore epigenetic regulation of PAH-
associated genes may offer novel therapeutic targets.38  
 
Sex hormone balance likely plays a role in PAH development, supported by experimental models 
of hormone regulation,39 and by observation that most PAH patients are female, and many female 
PAH patients are postmenopausal.40 Insulin resistance may also be more common in female versus 
male PAH patients, representing another risk factor or disease modifier in PAH.41 The 
relationships between insulin regulation, female gender, and mechanisms of PAH development 
remain unclear to date.  
 
Signs, Symptoms, and Clinical Management 
 
PAH patients present with the clinical signs and symptoms observed in pulmonary hypertension 
patients in general. Common symptoms include dyspnea, easy fatigability, generalized weakness, 
angina, and syncope, with symptoms at rest occurring at more advanced stages of the disease. 
Signs and symptoms of right heart failure, including jugular venous distention, ankle edema, 
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hepatomegaly, ascites, and abdominal distention worsen as the illness progresses. Other clinical 
signs include a right ventricular S3 heart sound, accentuation of the pulmonic component of the 
S2 heart sound, and possible pulmonic and tricuspid regurgitation.5 Current medical treatment may 
be divided into three steps,5,42 summarized here: 
 
1) Treatment with general measures (eg. supervised rehabilitation, birth control and post-
menopause hormone therapy, elective surgery, genetic counseling), supportive treatments 
(eg. digoxin, oxygen supplementation, diuretics), and acute vasodilator testing. 
2) Medical therapy initiated with high-dose calcium channel blockers in vasoreactive patients, 
or other drugs approved for PAH treatment in non-responders (eg. PDE5 inhibitors, 
endothelin receptor antagonists, prostacyclin analogs). 
3) Based on the patient response to steps (1) and (2) above, inadequate responders may be 
advised to consume drug combinations and/or be referred for lung transplantation. 
 
The genetic basis of PAH may have implications on clinical course and treatment. For instance, 
adult and pediatric PAH patients with BMPR2 mutations are not likely to respond to acute 
vasodilator testing during right heart catheterization, and calcium channel blockers therefore are 
less likely to provide therapeutic relief in these patients.43,44 Clinicians do not usually use genetic 
backgrounds of PAH patients to guide medical management of patients, though as we learn more 
about potential genotype-phenotype and treatment correlations in patients with disease-causing 
mutations, clinical management may be further refined.  
 
Genetic testing and counseling may be sought by select PAH patients in order to understand their 
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own genetic background of the disease (eg. to test for BMPR2 and other PAH-causing genetic 
mutations in themselves and their family members), and to guide reproductive decision-making. 
This includes deciding whether to undergo pre-implantation or prenatal genetic testing, to have no 




The incidence and prevalence of pediatric PAH is seemingly lower than in adult PAH, with a 
reported 0.7 and 4.4 cases of IPAH per million children, respectively, in the Netherlands.45 
Similarly, incidence and prevalence in the UK is 0.48 and 2.1 cases of IPAH per million children, 
respectively.46 IPAH, FPAH, and CHD-PAH are the most common causes of pulmonary 
hypertension in children, while pulmonary hypertension secondary to respiratory disease may be 
an important, underreported cause.47,48 
  
Pediatric PAH patients carry some genetic and clinical characteristics not found in the adult PAH 
patient population. The pathogenesis of PAH in infants and neonates is thought to arise from 
inadequate pulmonary vasculature dilation at birth.22 Distal resistance arteries experience 
abnormal muscularization, as well as a significant decrease in number. Intimal hyperplasia, vaso-
occlusion, and plexiform lesion may occur in children and adults.22  Prognosis in general is worse 
in children; before the advent of modern targeted treatments (eg. prostanoids), pediatric patients 
had a median survival of approximately 10 months, compared to a median survival of 2.8 years in 
adults. Prognosis and survival rates have improved in pediatric and adult PAH patient populations 
alongside newer medical treatments.49,50 
 
Fewer studies have been performed in children with PAH compared to adults, and the genetic basis 
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of PAH in children remains poorly understood overall. Genetic heterogeneity is greater in children 
than in adults, and PAH in children may occur in the setting of genetic syndromes, including with 
associated congenital heart disease, hepatic disease, and vascular disease, among other 
abnormalities.51-53 The mechanistic basis for the incomplete penetrance and variable expressivity 
of the underlying PAH-associated mutations also remains unclear. 
 
While similar signs and symptoms of PAH are seen in children and adults, there are key 
differences. For instance, syncope is more common in children than adults, and right ventricular 
failure may be a later manifestation of PAH in children. Children may die of sudden death prior to 
the development of right heart failure.47,50 A similar treatment algorithm in children to that used in 
adults has been developed, however this may be due to the relative scarcity of randomized 
treatment trials in pediatric PAH patients, contributing to difficulty in providing specific pediatric 
management recommendations.5,54,55 
  
Ion Channel Principles  
Ion channels are proteins embedded in phospholipid membranes that allow for passage of ions (eg. 
Na+, K+, Ca2+, and Cl-) between two cellular compartments, or between the intra- and extra-cellular 
compartments. Ion channels at the plasma membrane govern cellular excitability, and thus control 
numerous cell processes dependent on the cell type, including metabolism, growth, proliferation, 
and excitation-contraction coupling.4 Passage of ions through ion channels occurs by diffusion 
across the plasma membrane based on the ion’s driving force, or electrochemical gradient, and the 





The selectivity filter that resides within the conducting pore of the channel is composed of specific 
amino acid sequences, which allow for selective ion permeation.56 A variety of ion channels exist 
that respond to different extracellular and intracellular stimuli (eg. ligands, voltage, temperature, 
stretch, pH), which may activate or inhibit channel function. Given the focus of my thesis work on 
potassium channel function (and dysfunction) in pulmonary arterial hypertension, potassium 
channel structure and function will be exemplified here. 
 
Potassium Channel Structure and Function 
 
There are four classes of potassium channels (Figure I3): voltage-gated (Kv), calcium-activated 
(KCa), two-pore domain (K2P), and inwardly rectifying (Kir) potassium channels.28 Kv and KCa 
channels contain four pore-forming alpha subunits; each subunit contains six transmembrane 
segments (occasionally seven in KCa channels) and one pore (P-loop) domain. In general, Kv 
channels play critical roles in cellular repolarization and can contribute to the resting potential; 
KCa channels are regulated by intracellular calcium to control excitability.  
Figure I2.  Generic potassium and 
sodium ion channels at the plasma 
membrane. K+ and Na+ channels 
allow for selective permeation of ions. 
Potassium efflux and sodium influx 
predominate under physiological 





K2P channels (eg. KCNK3) contain four transmembrane segments and assemble as dimers; as their 
name suggests, each subunit within the functional dimer contains two pore (P-loop) domains. Kir 
channels (eg. KATP) possess alpha subunits with two transmembrane segments and one pore (P-
loop) domain; 4 Kir alpha subunits assemble to form the functional channel pore. Both K2P and 
KATP channels contribute background K+ currents to maintain the cellular resting potential. More 
details on these channels are provide below under the KCNK3 and KATP channel sections.  
 
Potassium Channels in Pulmonary Arterial Physiology 
 
A variety of potassium channels from all four K+ channel classes exist in PASMCs and PAECs. 
Physiologically, potassium channels play a major role in maintaining pulmonary arterial tone, and 
balancing vasoconstrictive and vasodilatory responses (Figure I4).  
 
Potassium channel activation leads to vasodilation by preventing activation of voltage dependent 
calcium channels (VDCCs), and thus keeping intracellular calcium concentrations low (Figure I4,  
Figure I3. Topology of the four potassium channel classes: Kv, KCa, K2P, and Kir. 
Reproduced from Foster and Coetzee,1 with permission.  
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bottom). Potassium channel inhibition or downregulation leads to depolarization, which activates 
VDCCs, resulting in an increase in intracellular calcium concentrations (Figure I4, top). Cytosolic 
calcium initiates excitation-contraction coupling in PASMCs, promoting vasoconstriction, and 
stimulates cell proliferation. As calcium concentrations rise in the cytosol and nucleus of the cell, 
a variety of calcium-dependent kinases are activated (eg. calmodulin kinase), in addition to various 
transcription factors such as NFAT. Activation of kinases and transcription factors promotes cell 
proliferation by steering the cell into the cell cycle.28,57 
  
Native PASMCs possess a resting potential of approximately -50mV.58,59 Based on physiological 
intracellular (~150 mmol) and extracellular (~5 mmol) K+ concentrations, the K+ equilibrium 
potential (EK) is approximately -80mV, derived from the Nernst equation. As such, there is an 
electrochemical driving force for potassium efflux from cells, which helps maintain the -50mV 
resting potential of native PASMCs in opposition to the counteracting inward flux of other 
permeant ions (eg. Na+, Ca2+) through selective and non-selective channels.59  
Figure I4. Potassium channels regulate 
excitability of PASMCs. Inhibition of K+ 
channels promotes PASMC membrane 
(Vm) depolarization, activating VDCCs 
leading to pulmonary artery constriction 
(top).  Activation of K+ channels promotes 
membrane hyperpolarization, inhibiting 
voltage-dependent calcium channels 
(VDCC) leading to pulmonary artery 
dilation (bottom).  
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Many gene transcripts for various alpha and beta channel subunits of Kv and KCa channels have 
been found in PASMCs, including at least 22 alpha-subunit genes of Kv channels, and three Kv 
channel beta-subunit genes,60 as well as four KCa alpha-subunit genes, and four KCa beta-subunit 
genes.61 Not all K+ channel proteins have been functionally assessed to date.  
 
The Kv1.2, Kv2.1, and Kv3.1 voltage-gated K+ channels are expressed in PASMCs,62-64 however 
these channel subunits activate at membrane potentials depolarized to -40mV,59,65 making it less 
plausible that these subunits contribute appreciably to the resting potential at -50mV. However, as 
voltage-gated potassium channels are comprised of four alpha subunits and heteromeric assembly 
of alpha subunits is known to occur, heteromeric Kv channel activity could  contribute to the resting 
potential.59 Indeed, whole-cell and single channel electrophysiological studies have shown that 
heterotetramers of Kv alpha subunits likely contribute  K+ currents in PASMCs.61 It was shown 
that Kv1.2/ Kv1.5, as well as Kv2.1/ Kv9.3 heteromers activate at potentials negative to -40mV, and 
therefore may play a role in setting the resting potential.62,63 This notion is supported by the fact 
that these heterodimeric channels demonstrate greater sensitivity to hypoxia than the 
corresponding homomeric Kv channels and therefore likely contribute to hypoxia-induced 
membrane potential depolarization.62,63  
 
The large-conductance Maxi- KCa alpha1 subunit is highly expressed in human PASMCs, along 
with expression of small-conductance SKCa isoforms.61 KCa and Kv channel activity both ultimately 
contribute to repolarization and to the resting potential to varying degrees, and in doing so control 




Other K+ channels contribute to PASMC excitability as well. For instance, the inwardly rectifying 
potassium channel subunits Kir2.1 and Kir2.4 were found to contribute significantly to whole-cell 
currents in cultured hPASMCs.70 Furthermore, a distinct K+ current, described as the non-
inactivating K+ current (IKN) in PASMCs, has been studied. Identified in multiple species,71-73 IKN 
is inhibited and/or downregulated by hypoxia, which may lead to PASMC depolarization and 
sequential activation of Kv currents.72,73 IKN channel opening was reported to occur at -70mV, with 
maximal channel current activation at -40mV, as it was speculated that there may be a voltage-
dependent component to IKN in PASMCs.59,71 Further studies suggested that the voltage-
independent two-pore domain KCNK3 potassium channel is a main contributor to IKN currents 
(see further details in the KCNK3 section, below).73,74 
 
Potassium channel regulation in PAECs influences pulmonary arterial diameter, including via 
cross-talk with nearby PASMCs. Enhanced potassium channel activity leads to plasma membrane 
hyperpolarization, a rise in cytosolic calcium concentrations, promoting nitric oxide release. Nitric 
Oxide acts on nearby PASMCs to promote vasodilation and prevent excessive proliferation. As 
such, background potassium conductances, such as those carried by the KCNK3 and KATP 
channels, can help control PAEC excitability and pulmonary arterial tone.1 In fact, in pulmonary 
hypertension, a downregulation of KCNK3 has been observed in PAECs, concomitant with 
PASMC depolarization and pulmonary vascular cell proliferation.75 Evidently, the dynamic 
regulation of pulmonary arterial diameter relies on potassium channel activity in both PAECs and 
PASMCs.   
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Hypoxic Pulmonary Vasoconstriction 
 
Resistance pulmonary arterioles respond to hypoxia by constricting.76 This phenomenon, termed 
hypoxic pulmonary vasoconstriction, is unique to the pulmonary arterial system. In systemic 
arteries, hypoxia promotes vasodilation, allowing the tissue in question (eg. skeletal muscle, liver, 
kidney, etc.) to extract enough oxygen from the blood to meet its metabolic demands. The primary 
purpose of pulmonary arterioles, however, is to extract oxygen from the alveolar spaces, in order 
transmit oxygen via the pulmonary veins to the left side of the heart, which pumps oxygenated 
blood throughout the body. Thus, hypoxia in a region of lung causes pulmonary arteriolar 
vasoconstriction, intended as a biological “safety mechanism” that shunts blood into pulmonary 
arterial branches travelling, ideally, to better oxygenated areas of lung. Hypoxia sensing 
mechanisms in pulmonary arteries in relation to potassium channel function have been studied, 
however a full understanding of the mechanisms underlying hypoxic pulmonary vasoconstriction 
remains elusive. 
 
Outside of the pulmonary arterial system, hypoxia may cause enhanced Kv currents and vascular 
smooth muscle cell hyperpolarization, which promotes vasodilation.77 In PASMCs, preferential 
downregulation of Kv channels in the setting of hypoxia contributes to the underlying mechanism 
of hypoxic pulmonary vasoconstriction and in pathological states leads to excessive pulmonary 
arterial constriction and proliferation, predisposing to PAH.77-80 In fact, downregulation of Kv 
channel functional is more specific to group 1 PAH than to PAH secondary to other diseases,80 
and thus represents a pathogenic disease mechanism.  
 
The Kv1.5 Channel in PAH 
 
In 2007, it was discovered that endothelin-1, a vasoconstrictor molecule, produces an inhibitory 
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effect on Kv1.5 channels.81 Given the established role of endothelin-1 in PAH pathogenesis, it was 
proposed that endothelin-1-mediated inhibition of Kv1.5 leads to excessive pulmonary 
vasoconstriction and medial hypertrophy of the pulmonary arterial wall in the setting of increased 
PASMC proliferation.81 Moreover, novel single nucleotide polymorphisms (SNPs) in the KCNA5 
gene that encodes Kv1.5 were identified in patients with IPAH, and it was suggested that SNPs in 
the translated and promoter regions of KCNA5 predispose IPAH patients to decreased expression 
and function of Kv1.5 channels in PASMCs.81 
  
Kv1.5 is preferentially expressed in small, resistance pulmonary artery smooth muscle cells, as 
opposed to larger pulmonary arteries that do not participate in hypoxic pulmonary 
vasoconstriction.76 Kv1.5 channel activity is inhibited by chronic and acute hypoxia (shown in 
PASMCs), which may lead to resistance pulmonary arterial remodeling via decreased Kv1.5 
expression over time.31,77,82,83 Kv1.5 channel regulation by hypoxia helps explain some of the 
mechanism underlying hypoxic vasoconstriction in Kv channel-rich resistance pulmonary arterial 
zones.82,84 Kv1.5 downregulation has been established in humans and in animal models of PAH as 
a pathogenic hallmark of PAH, however the overall mechanism of Kv1.5 downregulation by 
hypoxia remains incompletely understood.28,31,57,81  
 
Interestingly, transfection of the KCNA5 gene, encoding the Kv1.5 channel, into PASMCs, led to 
plasma membrane hyperpolarization and increased apoptosis.85 Thus, in theory KCNA5 gene 
transfer may represent a potential therapeutic avenue in PAH. In fact, in vivo KCNA5 adenovirus 
gene transfer via nebulizer into hypoxia-induced PAH rat lungs decreased pulmonary vascular 
resistance and caused pulmonary artery medial hypertrophy regression, while restoring hypoxic 
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pulmonary vasoconstriction.86  
 
KCNK3 in Pulmonary Arterial Physiology 
 
The non-inactivating current, IKN (described above), demonstrated robust sensitivity to 
extracellular pH in PASMCs.74 IKN was inhibited by extracellular acidosis to pH 6.3, a similar pH-
dependence conferred upon the acid-sensitive, two-pore domain KCNK3 channel. The KCNK3-
like IKN current was observed in multiple studies, including in human PASMCs.59,73,87 Given 
KCNK3’s largely voltage-independent, non-inactivating properties, it was suggested that the 
KCNK3 channel supplies a background current that contributes to the PASMC resting potential. 
 
Early physiological evidence of a role for KCNK3 in regulating pulmonary arterial vascular tone 
was provided by Gardener et al. in 2004,88 in a study that demonstrated KCNK3 expression in rat 
pulmonary arteries, and depolarization upon KCNK3 inhibition. More specifically, extracellular 
acidosis and anandamide (an endocannabinoid and KCNK3 inhibitor) produced depolarizations, 
while alkalosis hyperpolarized pulmonary arteries. In wire myograph experiments to measure 
changes in vessel diameter, application of anandamide caused small but appreciable 
vasoconstrictive responses.88  
 
In 2006, Olschewski and colleagues73 characterized the impact of KCNK3 channel expression in 
human PASMCs (hPASMCs). KCNK3 protein was present in primary and cultured hPASMCs in 
this study. KCNK3 mRNA expression was detected in hPASMCs as well, but the acid-sensitive 
KCNK5 and KCNK9 channels were not expressed in hPASMCs. mRNA expression of all three 
acid-sensitive K2P channels was detected in human brain tissue.73 
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On whole-cell patch clamp analysis, IKN in hPASMCs was studied by holding cells at 0 mV for a 
minimum of 5 minutes in order to isolate IKN by inactivating other voltage-dependent potassium 
currents,74 followed by application of a voltage ramp within the physiological voltage range, 
+60mV to -100mV. An anandamide-sensitive current was measured, and taken as a measurement 
of the KCNK3 current.73 The anandamide-sensitive current reversed near the calculated 
equilibrium potential for potassium (approximately -84mV), and measured IKN currents were pH-
sensitive, inhibited by acidosis and activated by alkalosis. 
 
Moreover, it was demonstrated that hypoxia inhibits IKN, and that anandamide has no significant 
effect on the cellular currents remaining in hypoxic conditions, suggesting that hypoxia and 
anandamide share a common target, KCNK3. Furthermore, transfection of siRNA targeted against 
KCNK3 lead to membrane depolarization. Along with the voltage-independent properties of 
KCNK3, the experimental results suggest that KCNK3 currents play a physiological role in 
contributing to the resting membrane potential of hPASMCs, and that by extension, KCNK3 
inhibition by hypoxia may serve a physiological role in hypoxic pulmonary vasoconstriction.73 
These lines of evidence supported the conclusion that KCNK3 current is a main contributor to IKN 





KCNK3 in PAH 
 
In 2013, our research group discovered the first channelopathy in pulmonary arterial hypertension. 
Using whole-exome sequencing, six novel missense variants (T8K, G97R, E182K, Y192C, 
G203D, and V221L) were identified in potassium channel subfamily K, member 3 (KCNK3), in 
six unrelated patients with familial and idiopathic PAH (Figure I5). The six patients did not have 
identifiable mutations in known PAH genes, including BMPR2, ALK1, CAV1, ENG, and SMAD9.3 
All six patients were heterozygous at the KCNK3 gene locus, possessing one mutant and one non-
mutant KCNK3 gene. Using in silico bioinformatic tools, all mutations were predicted to be 
damaging. Whole-cell patch clamp electrophysiological studies in COS7 cells expressing mutant 
versus wildtype KCNK3 channels confirmed loss of function for each mutant KCNK3 channel. 
Moreover, some mutant KCNK3 channels were pharmacologically rescued by ONO-RS-082, a 
phospholipase A2 inhibitor and KCNK3 activator. Therefore, we had identified loss of function 
Figure I5. KCNK3 mutations associated with PAH. Panel A shows the topology of the 
KCNK3 channel, with the locations of the six mutations associated with PAH. Panel B shows 
conservation of the mutated residues across two pore domain potassium channels. Reproduced 
with permission from 3, Copyright Massachusetts Medical Society. 
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KCNK3 mutations as a novel cause of familial and idiopathic PAH and potential therapeutic 
target.3  
 
In 2016, using a monocrotaline-induced pulmonary hypertension rat model, Antigny et al.75 
demonstrated that KCNK3 expression was reduced in pulmonary hypertension lungs, and that a 
corresponding reduction in functional KCNK3 channels was observed in freshly isolated PASMCs 
and PAECs, which was associated with plasma membrane depolarization. Moreover, prolonged 
application of the KCNK3 activator, ONO-RS-082, alleviated monocrotaline-induced pulmonary 
hypertension development, as evidenced by a reduction in right ventricular hypertrophy and right 
ventricular systolic pressure in rats exposed to both monocrotaline and ONO over 28 days, as 
compared to control rats exposed to monocrotaline alone over the same time span.75 These results 
highlight KCNK3 as a viable pharmacologic target in the treatment of pulmonary arterial 
hypertension.  
 
In addition, Antigny et al.75 observed reduced KCNK3 mRNA expression in pulmonary arteries of 
patients with idiopathic pulmonary arterial hypertension (IPAH), and reduced KCNK3 protein 
expression in lung tissues of patients with IPAH, signifying that KCNK3 expression and regulation 
play a role in the pathogenesis of pulmonary arterial hypertension due to any cause.   
 
The KCNK3 Potassium Channel   
 
The large potassium conductance across the plasma membrane was established decades ago, when 
the fundamental principles governing ion channel electrophysiology were studied.89-91 Potassium 
channels were thus known to contribute to the resting membrane potential, with a proportion of 
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current designated background (or “leak”) potassium current conducted through channel pores and 
obeying a current-voltage relationship based on the Goldman-Hodgkin-Katz constant field 
theory.89,92 By the mid 1990s, the voltage-gated, calcium-dependent, and inwardly rectifying 
potassium channels were cloned,89,93-95 and accounted for a large portion of the potassium 
conductance within cells, but a significant background potassium conductance was still yet to be 
identified.  
 
In 1996, however, the first TWIK channel (tandem of pore domains in a weak inward rectifying 
K+ channel) was cloned, giving rise to a new, emerging family of background potassium channels 
in mammals.96 From 1996 to 2003, the two-pore domain family grew to 15 total members, and 
each two-pore domain channel belonged to one of six subfamilies -- TWIK, TASK, TALK, TREK, 
THIK, or TRESK -- based on its functional properties and genetic sequence.89 
 
Cloning and Characterization of KCNK3  
The first TASK (TWIK-related acid-sensitive K+ channel) channel member, now referred to as 
TASK-1, was cloned from human kidney in 1996.97 TASK-1 was the third mammalian two-pore 
domain K+ channel discovered overall. By HUGO nomenclature, TASK-1 may be referred to as 
KCNK3 or K2P3.1.  In this dissertation, “KCNK3” will be used to describe the gene name as well 
as the potassium channel.  
 
KCNK3 consists of a 395 amino acid sequence, with four transmembrane segments, and two pore 
domains, as well as cytoplasmic N- and C-terminal domains that regulate channel trafficking and 
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expression. Functional KCNK3 channels form dimers from two channel subunits that co-
assemble.97 
 
Certain structural elements are shared by all members of the two-pore domain family. Each subunit 
within the functional dimer channel contains two pore-loop (“P-loop”) domains, and therefore four 
P-loops in total are present in the functional two-pore domain dimer channel. In contrast, other 
potassium channel families have structures containing one P-loop domain per channel subunit, 
with four P-loops in the functional channel as well, from assembly of four alpha subunits.89 All 
K2P mammalian family members possess a four transmembrane domain, two-pore domain 
structure (see Figure I5, above). Analysis of electrostatic interactions within the pore of two-pore 
domain channels suggests symmetry of the selectivity filter lining the channel pore, formed from 
two sets of  P1 and P2 loops.98 
  
Expression of KCNK3 was found in several tissues, including colon, small intestine, uterus > 
kidney, heart > lung, prostate > brain > placenta > pancreas.97 In electrophysiological studies of 
heterologous KCNK3 expression in COS cells and Xenopus oocytes, KCNK3 was characterized 
as a non-inactivating and K+ selective channel with Goldman-Hodgkin-Katz outward rectification, 
which predicts a curve in the current-voltage plot under asymmetric K+ concentrations.97 As such, 
the outward rectification observed with heterologous expression of KCNK3 currents is a 
consequence of the physiological asymmetric K+ concentration gradient inside and outside the cell, 
leading to varying driving forces for K+ across the physiological voltage range. Based on these 
properties, KCNK3 represents a time- and voltage-independent background potassium 
	 23	













Regulation of KCNK3 by Extracellular pH 
KCNK3 currents are extremely sensitive to extracellular pH within the physiological pH range, 
with approximately half-maximal activation (pK) observed at physiological pH 7.4. KCNK3 
currents are inhibited by extracellular acidosis and activated by alkalosis (Figure I6).97 
 
It was initially reported that extracellular acidosis inhibits KCNK3 with a pK value of 7.4, along 
with a Hill coefficient of 1.6, implying that both KCNK3 subunits within the functional dimer 
participate in pH sensing. Furthermore, intracellular pH alterations did not produce changes in 
KCNK3 currents.97 Given the voltage-independent properties of KCNK3, it was deduced that the 
pH sensor must reside in the extracellular portions of the channel, as opposed to within the 
Figure I6. KCNK3 channel regulation by 
extracellular pH. Panel A shows a generic 
cell expressing KCNK3. Extracellular 
acidosis inhibits KCNK3, diminishing 
potassium efflux, and alkalosis activates 
KCNK3, enhancing potassium efflux. Panel B 
shows a whole cell voltage clamp recording of 
KCNK3 expressed in COS7 cells. A voltage 
ramp was applied (-120mV to 60mV over 0.5 
seconds) every three seconds, from a -80mV 
holding potential. Physiological pH 7.4 
produces intermediate current activity (black 
curve), pH 6.4 (blue) reduces KCNK3 
current, and pH 10.4 (red) maximally 
activates KCNK3 current. 
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transmembrane electric field that bestows voltage-dependence upon, for instance, voltage-gated 
ion channels.97 By site-directed mutagenesis and electrophysiological analysis at varying 
extracellular pH, residue H98 was determined the main pH sensing residue, as mutation of H98 
significantly abolished the channel’s pH sensitivity. It was determined that the H72 and K210 
residues bestowed upon KCNK3 additional, relatively minor pH sensitivity.99 
 
 
KCNK3 Interactions with KCNK9 
KCNK9 (also known as TASK-3, or K2P9.1) was first cloned from rat cerebellum in 2000,100 and 
later in the same year, KCNK9 was cloned from human cerebellum.101 The KCNK9 gene encodes 
the KCNK9 channel, a 374 amino acid protein that shares 62% sequence homology with human 
KCNK3. Rat and human KCNK9 share 74% amino acid sequence homology,101 with significant 
differences in sequence observed 3’ to the fourth transmembrane domain. In the initial 
characterization of human KCNK9, a pK value (pH at half-maximal activation) of approximately 
6.5 was reported.101 The Hill coefficient for the pH dependence of KCNK9 was close to 2, 
suggesting (as for KCNK3 channels) that both KCNK9 subunits participate in pH sensing within 
the functional dimer channel.100 The H98 residue in KCNK9 is the major pH sensing residue.100,102 
KCNK9 shares the most structural resemblance to KCNK3, and evidently both channels are 
inhibited by extracellular acidosis and activated by extracellular alkalosis. However, KCNK9 is 
more maximally activated at physiological pH 7.4, while KCNK3 is more tightly regulated within 
the range of physiological pH 7.4. 
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KCNK3 and KCNK9 channel subunits form functional heterodimers with one another, with 
heterodimeric channels containing one subunit each of KCNK3 and KCNK9. Heterodimerization 
of KCNK3 with KCNK9 is the only known heteromeric association within the K2P channel family, 
and adds to the complexity of the channels’ regulation and electrophysiology.89 
 
The homodimeric KCNK3 and KCNK9 channels possess distinct electrophysiological and 
pharmacological properties, while the heterodimeric KCNK9-KCNK3 channels display mixed 
phenotypes that are not always intermediate in function compared to the homodimeric parent 
channels.89,103 For instance, the ruthenium red dye and zinc (Zn2+) have been shown to inhibit 
KCNK9 homodimeric channels, while KCNK3 homodimers and KCNK9-KCNK3 heterodimers 
are not inhibited by either agent.89,103-105 The pH sensitivity of the heterodimeric channels is 
intermediate, with a pK value that lies between the pK values of the homodimeric channels. The 
single-channel conductance of the heterodimer, meanwhile, is equal to that of KCNK9 channels 
in the presence of extracellular Mg2+ ions.106,107 In the absence of extracellular Mg2+, the single 
channel conductance of the heterodimer is intermediate between that of KCNK3 and KCNK9 
homodimeric channels.89,107   
 
To date, KCNK9-KCNK3  heterodimeric channels have been studied in a variety of native tissues, 
including in cerebellar granule neurons,106 motoneurons,108 rat carotid body glomus cells,107 lateral 
geniculate thalamocortical relay neurons,109 hippocampal interneurons,110 and in cardiac atrial 
myocytes.111 Functional diversity depends on the degree of hetero- and homo-dimerization of the 
two channel subunits and relative proportions of the assembled channels.89  
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Berg et al.108 determined that hypoglossal motoneurons expressed both KCNK3 and KCNK9 
mRNA, and suggested that a significant component of its background potassium channel current 
consistent is derived from KCNK9-KCNK3 heterodimeric channel currents. This was evidenced 
by the intermediate pH sensitivity of the heterodimeric channel currents compared to monomer 
KCNK3 or KCNK9 currents, as well as activation by Isoflurane, a pharmacological feature of 
KCNK9, but not KCNK3 channels, which are inhibited by isoflurane. The effects of isoflurane 
could not be attributable to KCNK9 monomeric channel expression as these channels had been 
blocked by the KCNK9 specific inhibitor, ruthenium red. Heterologous expression of monomeric 
and heteromeric channel assembly supported these results, as it demonstrated an intermediate pH 
sensitivity for KCNK9-KCNK3 heterodimers (pK ~ 7.3), compared to monomeric KCNK3 (pK ~ 
7.5), and monomeric KCNK9 (pK ~6.8) channel activity in this study.108 
 
In cultured cerebellar granule neurons, Kang et al. identified the functional features of KCNK9-
KCNK3 heterodimers; the potassium channel currents had an extracellular pH sensitivity that was 
intermediate between KCNK3 and KCNK9 monomer channel expression, and displayed reduced 
sensitivity to inhibition by ruthenium red, as compared to KCNK9 monomer channel 
expression.106 These two lines of functional evidence demonstrated the presence of KCNK9-
KCNK3 heterodimer formation. The electrophysiological evidence for heterodimer formation was 
replicated by heterologous expression of channel subunits in COS-7 cells. The consistency of the 
functional assays in native and heterologous expression systems also demonstrated the utility of 





Anandamide was first reported as a specific KCNK3 inhibitor, within the two-pore domain channel 
family.112 As such, anandamide was employed as a pharmacological tool to dissect the contribution 
of KCNK3 currents in various tissues, including in pulmonary artery smooth muscle cells.73 While 
anandamide indeed potently inhibits KCNK3, it is no longer considered a specific KCNK3 
blocker, as KCNK9 is blocked by anandamide with similar potency.89,113 Furthermore, 
anandamide and/or other endocannabinoids inhibit other ion channels, including TRPV1,114 
Na+,115 T-type Ca2+ channels,116 and Shaker-related Kv channels.117 Ruthenium red, on the other 
hand, inhibits KCNK9 and has no appreciable effect on KCNK3 channels and thus can be 
employed as a specific KCNK9 blocker in this context.89,105,106 
 
Streit et al.118 studied the effects of A1899, an experimental compound described as a potent and 
selective blocker of KCNK3. Through alanine mutagenesis screening of the KCNK3 channel in 
parallel with electrophysiological studies, the following sites were determined to likely form the 
binding sites for A1899 intracellularly, leading to KCNK3 inhibition: (a) residues in the M2 and 
M4 transmembrane segments, including residues that comprise the “halothane response element” 
(amino acids “VLRFMT” at positions 243-248 in the KCNK3 sequence; both the KCNK3 and 
KCNK9 channels are targets of anesthetic agents119,120); (b) residues in each pore loop including 
within the potassium selectivity filter (sequence “TTIGYG in P1 loop, and TTIGFG in P2 loop, 
with the bolded threonine sites likely serving as binding sites for A1899). Based on the sites of 
channel block, the authors strongly suggested that A1899 inhibits KCNK3 currents by binding 
deep within the channel pore to act as a plug to inhibit current.118 This study provides insights into 
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the structural basis for pharmacological KCNK3 inhibition, to aid the development of KCNK3 
inhibitors and activators for experimental and clinical use. 118  
 
Of the amino acids in the M2 and M4 segments of KCNK3 identified as components of the A1899 
binding site, there is approximately 90% sequence homology with the KCNK9 channel. This 
would explain shared inhibiting or activating profiles among certain pharmacological compounds 
on the KCNK3 and KCNK9 channels, and the difficulty in developing fully selective 
pharmacological agents via binding to the channel’s pore.118  Newer experimental compounds have 
since been employed as KCNK3 modulators. Please refer to Chapter 1 for experimental results 
using the recently developed KCNK3 inhibitor, ML365, and the KCNK3 activator, ONO-RS-082. 
 
KATP in Pulmonary Arterial Physiology  
 
There is relatively less known about the contributions of ATP-sensitive K+ channels (KATP) to the 
resting potential in PASMCs and their contributions to cell excitability in physiological and 
pathophysiological conditions.121-123 It has been suggested that a mitochondrial KATP channel may 
contribute to regulation of pulmonary arterial remodeling and contraction via mitochondrial 
metabolic and signaling pathways.124 
 
In 1992, it was determined that intracellular levels of ATP regulate the resting membrane potential 
of PASMCs via inhibition of potassium channels,125 and it was proposed that KATP channel 
currents contribute to maintenance of the resting potential in PASMCs. This conclusion was drawn 
by lowering intracellular ATP in the patch pipette from 1mM ATP to 0 mM ATP, and observing 
a change in the resting potential from -55mV to -70mV. At the hyperpolarized potential of -70mV, 
glibenclamide, a KATP channel blocker, led to significant membrane depolarization, which 
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suggested that the hyperpolarization induced by a decrease in intracellular ATP levels was due to 
activation of the KATP channels in PASMCs.125 
 
Additional studies have attempted to characterize the subunits underlying KATP function in 
pulmonary artery smooth muscle and endothelial cells. In the first critical investigation of KATP 
channel subunits in human pulmonary arteries, it was reported that Kir6.1 and SUR2B were the 
predominant alpha and beta subunit isoforms, respectively.126 Importantly, however, the gene 
expression analysis of channel subunits was derived from RNA from cultured hPASMCs, and the 
authors note that suppression of KATP channel activity was observed for proliferating cells in 
culture.126 Given the downregulation of potassium channels that occurs in PASMCs in culture,32 
it is possible that other isoforms of KATP channels subunits (eg. Kir6.2, SUR1, and SUR2A) are 
more abundant in native PASMCs. Expression of KATP subunits in freshly isolated, native human 
PASMCs was not performed, however expression of KATP subunits from intact rat pulmonary 
artery produced differing results, as SUR1 expression was observed in addition to Kir6.1 and 
SUR2B.126 Thus, it is plausible that certain cellular and/or physiological conditions alter 
expression of KATP channel subunits in pulmonary arteries in general, and PASMCs in particular.  
Both SUR1 and SUR2B expression were reported in guinea-pig bladder SMCs,127 suggesting that 
heteromerization of SUR1 with SUR2B may occur in certain smooth muscle tissue types, adding 
to the complexity of KATP regulation in smooth muscle cells. 
 
SUR Subunits of the KATP Channel 
Sulfonylurea receptor 1 (SUR1), encoded by the ABCC8 gene, was first cloned from pancreatic 
beta cells in 1995.128 Highest levels of SUR1 mRNA expression were found in the pancreas, heart, 
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and brain.1,128 SUR2A and SUR2B, two splice variants of the ABCC9 gene, were discovered 
shortly after.129,130 SUR2B was found to be expressed ubiquitously, while SUR2A expression was 
found to be high in skeletal muscle, heart, and ovary, with moderate expression found in brain, 
pancreas (not insulin-secreting cells), and tongue.1,129,130 
The SUR proteins are all beta subunits of the pore-forming Kir6.1 and Kir6.2 alpha subunits of the 
KATP channel. SUR1 and SUR2A/B are encoded by the ABCC8 and ABCC9 genes, respectively, 
which belong to the superfamily of ATP-binding cassette (ABC) proteins.1 The SUR proteins 
harbor intracellular nucleotide-binding folds, which participate in regulation of the KATP channel 
via nucleotide binding. The SUR proteins have 17 transmembrane segments that are subdivided 
into three transmembrane domains: TMD0, TMD1, and TMD2 (Figure I7).1 
 
KATP Channel Structure and Function 
The pore-forming alpha subunits of the KATP channel, Kir6.1 and Kir6.2, were identified in 1995 in 
quick succession.131,132 Belonging to the inwardly-rectifying potassium channel subfamily, a single 
Figure I7. Topology of SURx and Kir6.x subunits. The SURx proteins (eg. SUR1, 
SUR2A, and SUR2B) have 17 transmembrane segments, divided into transmembrane 
domains (TMD) TMD0, TMD1, and TMD2. Two cytoplasmic loops contain nucleotide 
binding folds (NBF1 and NBF2). The Kir6.x alpha subunits (eg. Kir6.1, Kir6.2) have two 
transmembrane segments and one P-loop. Four alpha subunits assemble to form the 
inner pore of the KATP channel. Reproduced with permission from Foster and Coetzee1.  
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Kir6.1 and Kir6.2 subunit is composed of two transmembrane segments and one pore-forming 
domain, denoted the “P loop,” which resides between transmembrane segments TM1 and TM2,133 
which contains the potassium selectivity filter within it (see Figure I7).133,134 Potassium selectivity 
in Kir channel subunits is governed by the signature amino acid sequence T-I-G-[Y or F]-G within 
the pore domain.1 Four alpha subunits assemble to form the potassium selective channel pore. Four 
beta subunits (eg. SUR1, SUR2A, and/or SUR2B) assemble circumferentially around the pore-
forming alpha subunits and in doing so regulate channel function and expression (Figure I8A).1 
This mode of assembly was specifically confirmed for SUR1/ Kir6.2-containing KATP channels, in 
studies that demonstrated a 1:1 stoichiometry of assembly between SUR1 and Kir6.2,135,136 
characterized as an octameric or tetradimeric co-assembly of SUR1 with Kir6.2, with the four 
Kir6.2 subunits forming the channel pore (Figure I8).137 
 
KATP channels are extremely sensitive to intracellular ATP concentrations, as intracellular ATP 
decreases the open-probability of KATP by an inverse relationship.1,138-140 Nonhydrolyzable ATP 
analogs block KATP, demonstrating that ATP itself is a direct substrate for KATP channel inhibition, 
and hydrolysis of ATP is not a necessary step involved in ATP’s inhibition of the channel.1,141 Free 
intracellular ADP also blocks KATP channels, however ADP is approximately 10-20 fold less 
potent than free ATP channel block.1,141,142  While free ADP blocks KATP channels, it is of 
significant physiological consequence that MgADP activates KATP by stimulating channel 
opening. The degree of channel inhibition/activation is thus not solely determined by intracellular 
ATP concentration, but rather is heavily influenced by the intracellular ATP/ADP ratio.143  
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KATP channels are open and active across the physiological voltage range, and at the plasma 
membrane contribute to the negative resting potential via potassium efflux. KATP channels exhibit 
relatively weak inward rectification within the Kir family of potassium channels. As such, KATP 
channels produce appreciable outward current at more depolarized membrane potentials compared 
to strong inwardly rectifying potassium channels that produce minimal outward potassium current 
at depolarized potentials (Figure I8B).1,144 KATP channels are not voltage-gated, but rather are 
voltage-sensitive in the sense that their inwardly-rectifying properties lead to disproportionately 
less conduction of potassium at more depolarized membrane potentials. Both Na+ and Mg+ ions 
Figure I8. Assembly of functional (SUR1/ Kir6.2) KATP channels.  Panel A 
demonstrates that KATP channels form by the assembly of four inner pore-forming Kir6.2 
alpha subunits (blue), in association with four SUR1 beta subunits that encircle the pore 
forming alpha subunits (red). Panel B shows a whole-cell voltage clamp recording in 
COS7 cell of expressed (SUR1/ Kir6.2) KATP channel currents. A voltage ramp from -
120mV to 60mV over 1 second was applied every 3 seconds from a -80mV holding 
potential. The KATP activator, diazoxide 100uM (black), maximally activated the KATP 
current, and co-application of the SUR1 inhibitor, glibenclamide 10uM (red), inhibited 
the current. Weak inward rectification of current is observed. Sample current traces are 
shown. The vertical scale is 100pA/pF; the horizontal scale is 20mV. Panel A reproduced 
from Foster and Coetzee,1 with permission. 
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have been shown to block outward KATP -mediated potassium current, thought to contribute to the 
channel’s inward rectification.1,145,146 
 
KATP channels are potently inhibited by intracellular ATP, with an IC50 for channel block of ~ 100 
µM originally reported from inside-out patch experiments in ventricular cardiomyocytes.1,138  
Importantly, additional studies have determined that the heterologous co-expression of SUR1 with 
Kir6.2 greatly enhanced sensitivity of KATP channel inhibition by ATP; heterologous expression of 
Kir6.2 alone had an IC50 of approximately 140 µM,1,147 while co-expression of SUR1 with Kir6.2 
enhanced the inhibitory effects of ATP (IC50 of approximately 15 µM).144 It is believed that ATP’s 
main inhibitory effect on SUR1/ Kir6.2 KATP channels occurs via its binding to the Kir6.2 subunits, 
and that ATP sensitivity of the mature channel is potentiated, via an undetermined mechanism, 
when SUR1 and Kir6.2 subunits co-assemble. It appears, perhaps ironically, that ATP sensitivity 
conferred upon SUR1/Kir6.2 KATP channels is not significantly caused by ATP binding to 
SUR1’s NBF regions, as mutagenesis experiments in NBF1, NBF2, and the linker region between 
the NBF regions did not prevent channel inhibition by ATP.1,148 Instead, it appears that the NBF 
regions of SUR1 confer tremendous sensitivity to KATP channel activation by MgADP and 
diazoxide.148,149  
 
It has been proposed that SUR1 sensitizes the KATP channel to ATP inhibition, but at the same time 
the NBFs within SUR1 hydrolyze nucleotides, blocking the inhibitory effect of ATP on the KATP 
channel. MgADP and diazoxide, meanwhile, are thought to contribute to KATP desensitization of 
the inhibitory effects of ATP, thereby promoting channel activation.149 Further evidence that 
MgADP activates SUR1/ Kir6.2 KATP channels via its binding to SUR1 came from a study in which 
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Kir6.2 expression alone was not activated by MgADP.150 Adding to the complexity of nucleotide 
interactions with SUR1/ Kir6.2, MgATP, like MgADP, is capable of KATP activation via binding 
to SUR1, however the high potency of free ATP inhibition of KATP generally supersedes, or masks, 
the activating effects of MgATP.150 The exact mechanism by which SUR1 assembly with Kir6.2 
enhances channel sensitivity to ATP inhibition remains unclear.1 
 
KATP (SUR1/ Kir6.2) in the Pancreas and Related Pharmacology 
SUR1/ Kir6.2-containing KATP channels have been most well characterized in the beta cells of the 
pancreas. At baseline, KATP channels are open, leading to potassium efflux. In the fed state, levels 
of glucose rise in the beta cells, which promote cellular respiration and an increase in the 
intracellular ATP/ADP ratio. Higher relative ATP concentrations inhibit KATP currents, leading to 
cell depolarization, which activates voltage-gated calcium channels. Next, calcium influx 
promotes exocytosis of vesicle containing insulin, which are released into the blood to regulate 
blood glucose levels. As such, gain-of-function mutations in ABCC8 and KCNJ11 can cause 
diabetes mellitus due to impaired insulin release from the beta cells, while loss-of-function 
mutations are associated with congenital hyperinsulinism.  
 
SUR1 is the target of sulfonylurea drugs, such as glibenclamide, which inhibit SUR1/ Kir6.2 KATP 
channel currents via their binding to SUR1, leading to pancreatic beta cell depolarization and 
enhanced insulin release. Glibenclamide is clinically employed in patients with diabetes mellitus. 
Diazoxide is a KATP channel (and SUR1) activator that requires intracellular ADP for efficacy.1 
Diazoxide causes vasodilation151 and hyperglycemia,152 due to activation of KATP channel isoforms 

























CHAPTER 1:  
 
THE IMPACT OF HETEROZYGOUS KCNK3 MUTATIONS 
ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION  





Background- Heterozygous loss of function mutations in the KCNK3 gene cause idiopathic and 
familial pulmonary arterial hypertension (PAH). KCNK3 encodes an acid-sensitive potassium 
channel, which contributes to maintenance of the resting potential of human pulmonary artery 
smooth muscle cells. KCNK3 is widely expressed in the body, and dimerizes in vivo with other 
KCNK3 subunits, or the closely related, acid-sensitive KCNK9 channel. We assessed the impact 
of KCNK3 mutations on channel function in homozygous and heterozygous cellular models of 
mutant channel expression to determine the pathophysiological and therapeutic implications in 
PAH. 
 
Methods and Results- We engineered homomeric and heterodimeric mutant and nonmutant 
KCNK3 channels associated with PAH, and created a platform for the comparison of mutant 
versus wildtype KCNK3 channel function and pharmacology. Whole-cell patch clamp 
electrophysiology was performed in human pulmonary artery smooth muscle and COS7 cell lines. 
We determined that the homomeric and heterodimeric assembled channels in heterozygous 
KCNK3 conditions leads to mutation-specific severity of channel dysfunction, with a unique pH-
dependent mechanism of dysfunction conferred upon the V221L KCNK3 mutant channel. Both 
wildtype and mutant KCNK3 channels were activated by ONO-RS-082 (10uM) in cultured human 
pulmonary artery smooth muscle cells causing cell hyperpolarization. We observed robust gene 
expression of KCNK3 in healthy and familial PAH patient lungs, but no quantifiable expression of 
KCNK9, and demonstrated in functional studies that KCNK9 minimizes the impact of select 
KCNK3 loss of function mutations when the two channel subunits co-assemble.  
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Conclusions- Heterozygous KCNK3 mutations in PAH leads to variable loss of channel function 
via distinct mechanisms. Homomeric and heterodimeric mutant KCNK3 channels represent novel 
therapeutic substrates in PAH. Pharmacological and pH-dependent activation of both wildtype and 
mutant KCNK3 channels in pulmonary artery smooth muscle cells leads to membrane 
hyperpolarization. Co-assembly of KCNK3 with KCNK9 subunits can minimize the impact of 
KCNK3 loss of function mutations and therefore KCNK9 can provide protection against KCNK3 
loss of function in tissues where both KCNK9 and KCNK3 are expressed, contributing to the lung 

































Pulmonary arterial hypertension (PAH) is a progressive illness characterized by intimal 
hyperplasia and medial hypertrophy of pulmonary arteries, leading to increased pulmonary 
vascular resistance, right-sided heart failure, and high mortality rates.155 A primary disease process 
of the lung defined by a mean pulmonary arterial pressure ³ 25 mmHg, pulmonary artery 
endothelial and smooth muscle cell proliferation and excessive vasoconstriction represent 
pathogenetic mechanisms in PAH. Mutations in the BMPR2 gene, a component of the transforming 
growth factor-b signaling pathway, account for most genetic cases of PAH, while less frequently, 
mutations in other genes underlie the disease.5 
 
We recently identified KCNK3 as the first ion channelopathy associated with PAH.3 Using exome 
sequencing, six distinct mutations in the KCNK3 potassium channel were identified in patients 
with familial and idiopathic PAH. All patients were heterozygous at the KCNK3 gene locus, 
possessing one mutant and one wildtype (WT) channel. Each of the six KCNK3 mutations led to 
loss of channel function, and some mutant channels were functionally rescued by ONO-RS-082 
(ONO), a phospholipase A2 inhibitor and KCNK3 activator.3 
  
KCNK3 encodes an acid-sensitive two-pore domain potassium channel (also referred to as TASK-
1), known for its extreme sensitivity to extracellular pH, especially within the range of 
physiological pH 7.4.97 Strongly inhibited by extracellular acidosis and hypoxia, KCNK3 regulates 
cellular excitability, and is thought to contribute to hypoxic pulmonary vasoconstriction.73 The 
voltage-insensitivity of KCNK3 renders the channel open across all voltages, leading to potassium 
efflux from cells expressing the channel, which contributes to the negative resting potential. 
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KCNK3 is widely expressed in the human body, including in the central nervous system, heart, 
adrenal glands, and PASMCs.74,89  
 
KCNK3 currents contribute to the resting potential of native human pulmonary arterial smooth 
muscle cells (hPASMCs) and impact pulmonary arterial tone and smooth muscle cell growth, 
while KCNK3 downregulation or inhibition leads to PASMC depolarization, proliferation, and 
pulmonary arterial constriction.73-75,88 Notably, KCNK3 downregulation was recently identified as 
a pathogenic hallmark of PAH in humans and in a monocrotaline-induced pulmonary hypertension 
rat model, and administration of ONO alleviated signs of pulmonary hypertension in the animal 
model, further implicating KCNK3 as a therapeutic target in PAH.3,75  
 
KCNK3 dimerizes in vivo, forming functional channels from two subunits linked together.156 
Adding to the complexity of KCNK3 channel interactions, the closely related acid-sensitive 
KCNK9 channel dimerizes with KCNK3, forming KCNK9-KCNK3 heterodimeric channels in 
tissues where both channels are expressed.103,106-108,111 KCNK9 is more maximally activated at 
physiological pH 7.4 than KCNK3.100,102 The channels are co-expressed in a variety of tissues, 
promoting tissue-specific diversity of channel function. Importantly, KCNK3, but not KCNK9, 
has been shown to be expressed in hPASMCs.73  
 
In this study, we investigate: (1) mechanisms of heterozygous KCNK3 loss of function mutations 
in PAH by studying channel function over a broad pH range; (2) the capacity of mutant and 
wildtype KCNK3 channels to serve as therapeutic targets in PAH; (3) the impact of selected 
KCNK3 mutations on channel function and pharmacology in physiologically relevant 
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heterozygous conditions; and (4) the potential role for KCNK9 in underlying the lung-specific 





Human lung parenchymal samples were obtained from 10 control patients with healthy lungs 
(failed donor lungs); seven were female, three were male. Samples from patients with familial 
pulmonary arterial hypertension (FPAH) were obtained; three were female, two were male. 
Samples from patients with congenital cardiac defect -associated pulmonary arterial hypertension 
(APAH) were obtained; five patients were female. cDNA samples were provided by the 
Pulmonary Hypertension Breakthrough Initiative (PHBI).157 The protocol, “Studying Gene 
Expression in Pulmonary Arterial and Lung Tissue in Healthy and Diseased Samples,” 
(#AAAQ2454) was approved by the Institutional Review Board at Columbia University Medical 
Center. KCNK3 mutations in PAH patients were identified as previously reported.3   
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
The TaqMan gene expression system was used to quantify mRNA expression (Applied 
Biosystems). RNA and cDNA from lung samples were prepared for gene expression analysis using 
a previously described protocol.157 No-template controls lacking cDNA were included, to verify 
the specificity of the assay at recognizing cDNA templates of interest. Experiments were 
performed in duplicate for each sample. Data are expressed as means of the average cycle threshold 
(Ct) value of duplicates, and as fold changes in expression (2ddCt method). Commercially available 
assays from Applied Biosystems were used for priming/probing of cDNA samples, including:  
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1) KCNK3 (Assay ID= Hs00605529_m1) 
2) KCNK9 (Assay ID= Hs00363153_m1) 
3) GAPDH (Assay ID= Hs02758991_g1)  
 
Expression of KCNK3 and KCNK9 in PAH and control lungs was normalized to GAPDH 
expression. Average cycle threshold (Ct) values at which signals for each gene appeared were 
calculated based on 40-cycle assays. For samples in which no amplification signal was produced, 
a Ct value of “40” was assigned for the purpose of calculating mean Ct values. 
 
Molecular Biology 
Mutations were engineered into human KCNK3 cDNA in a pcDNA3.1+ expression vector by site-
directed mutagenesis using QuickChange (Stratagene).3 Human KCNK9 cDNA in a pIRES-GFP 
and pcDNA3.1+ vector was used. Where noted, KCNK3 constructs were tagged with a C-terminal 
green fluorescent protein (GFP). Tandem-linked KCNK3-KCNK3 and KCNK9-KCNK3 dimer 
constructs were engineered in pcDNA3.1+ vectors by joining two KCNK subunits with a glycine-
rich linker (the vector sequence from the AFLII to BAMHI restriction sites plus 5 glycine 
residues), and subcloning into a pcDNA3.1+ vector. 
 
Materials 
ONO-RS-082 (Enzo Life Sciences), ML365 (MedChem Express), and ruthenium red and DMSO 
(Life Technologies) were purchased commercially. ONO-RS-082 and ML365 were dissolved in 
DMSO and ruthenium red in water in 100mM stock solutions and stored at -20°C. Drugs were 
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diluted to 10µM in drug-containing external solutions, and DMSO 10µM was added where 
appropriate to control (drug-free) solutions. Lipofectamine, Lipofectamine LTX, and Plus Reagent 
(Invitrogen) were used for transfection. 0.25% Trypsin/EDTA and Trypsin Neutralizer (Gibco) 
were used for splitting cell cultures. Human pulmonary artery smooth muscle cells (Gibco) were 
grown in Smooth Muscle Growth Medium-2 with supplements (SmGM-2 bulletkit, Lonza). COS7 
cells (American Type Culture Collection) were cultured in medium containing DMEM 1X + 
GlutaMAX-1 with 4.5g/L D-Glucose and 110mg/L Sodium Pyruvate (Gibco), and supplemented 
with 10% Fetal Bovine Serum (Gibco) and 1% Penicillin/Streptomycin (Gibco).   
 
Cell Culture and Heterologous Channel Expression 
KCNK3 and KCNK9 channel constructs were expressed in cultured hPASMC and COS7 cell lines. 
GFP (in a pcDNA3.1+ vector) was co-expressed or tagged to the C-terminus of the channel as a 
marker of transfection. A previously established transfection protocol using Lipofectamine 
reagents was employed in COS7 cells 3, with modifications to optimize efficiency in hPASMCs. 
 
COS7 cells: 
On day 0, a T25 flask ~40-50% confluent was transfected with KCNK3 or KCNK9 cDNA using 
the following protocol: 2µg of KCNK3 or KCNK9 cDNA (20µl from a stock solution of 0.1µg/µl 
cDNA) + 1µg GFP if the KCNK3 construct was not GFP-tagged + 20µl PLUS reagent + OptiMEM 
medium supplemented with L-glutamine up to 200µl were mixed and incubated at room 
temperature for 20 minutes. Of note, for co-expression of two KCNK3 (or KCNK3 + KCNK9) 
constructs, 1.5µg of each cDNA was transfected. 
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Next, 20µl Lipofectamine + 180µl OptiMEM medium supplemented with L-glutamine were added 
to the cocktail and incubated for 20 additional minutes at room temperature. Next, 1.6ml of 
OptiMEM supplemented with L-glutamine was added to the cocktail and mixed, and the 2ml 
transfection cocktail was pipetted into the COS7 cell flask after removal of the culture medium. 
The flask was returned to the 37°C cell culture incubator (conventional growth conditions, 5% 
CO2) for approximately 4-6 hours. After incubation, the transfection cocktail was replaced by 
COS7 culture medium.  
 
On day 1 in the afternoon, cells transfected on day 0 were split into 10cm dishes in the culture 
hood as follows: culture medium was removed from the T25 flask, and 5ml of 1X PBS was quickly 
added and removed, before 2ml 0.25% Trypsin/EDTA was added to the flask. The flask was then 
placed back in the 37°C incubator for approximately 5 minutes. After cells were dislodged from 
the flask bottom, 5ml of cell medium was added to the flask and pipetted to dislodge more cells. 
The 7ml cell solution was pipetted out of the flask and transferred into a 15ml conical tube, and 
centrifuged for 1.5 minutes at 1xg. The conical tube was returned to the culture hood, medium 
removed, and new cell medium added for cell suspension. Cells were then pipetted into 10cm 
dishes, and placed back in the 37°C incubator. On day 2 (and day 3 if cells were still healthy), the 
10cm dishes were used for patch clamp experiments.   
 
Human Pulmonary Artery Smooth Muscle Cell Line: 
In hPASMCs, transfection of KCNK3 cDNA required the following protocol: On day 0, hPASMCs 
in a T25 flask were split into 10cm dishes suitable for patch clamp experiments. Cells were split 
using the manufacturer’s protocol (Gibco), which required 0.25% Trypsin/EDTA for cell 
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detachment from the flask, and Trypsin Neutralizer to resuspend cells before plating in 10cm 
dishes. Cells were grown in supplemented Smooth Muscle Growth Medium-2 (Lonza). 
 
On day 1, cell were transfected under the culture hood, as follows: per 10cm dish, 0.6µg KCNK3 
cDNA tagged with GFP at the C-terminus (from a cDNA stock solution of 0.1µg/µl) + 0.6µl PLUS 
reagent + 50µl OptiMEM medium supplemented with L-glutamine, were mixed and incubated at 
room temperature for 10 minutes. Next, 1.5µl Lipofectamine LTX per dish was added to the 
cocktail and incubated for an additional 30 minutes at room temperature. Equal proportions 
(58.1µl) of the cocktail were then pipetted into each 10cm dish, and dishes were returned to the 
37°C incubator. On day 2 (and day 3 if cells were still healthy), 10cm dishes were used for patch 
clamp experiments.  
 
Electrophysiology 
KCNK3 channel current and membrane potential changes were recorded by whole-cell patch 
clamp in hPASMCs and COS7 cells. An Axopatch 200B amplifier (Axon Instruments), Digidata 
1440A model, and pClamp 10 software were used for recording and analysis (Molecular Devices, 
CA). Pipette resistances generally ranged from 1-4 MOhm. For all voltage clamp experiments, 
cells were held at -80mV and a 500ms voltage ramp was applied once every 3 seconds, with 
voltage increasing linearly from -120mV to +60mV before returning to holding. Expressed 
KCNK3, KCNK9, and tandem dimer constructs were recorded. For current clamp experiments, 
changes in membrane potential were recorded over time after first applying the voltage ramp to 
verify stability of the patch and expression of KCNK3 channels. 
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Perfusion of extracellular solutions containing pharmacological agents or different pH values 
occurred at recorded intervals during patch clamp experiments, at room temperature under 
normoxic conditions. All experiments with pharmacological agents were conducted at 
extracellular pH 7.4.  
 
For experiments in COS7 cells, solutions were prepared as previously reported 3:  pipette (internal) 
solution (in mmol/L) contained: 150 KCl, 3 MgCl2, 5 EGTA, 10 HEPES, adjusted to pH 7.2 with 
KOH. Bath (extracellular) solution (in mmol/L) contained: 150 NaCl, 5 KCl, 1 MgCl2, 1.8 CaCl2, 
10 HEPES adjusted to pH 6.4, 7.4, or 8.4 with NaOH.  
 
For experiments in hPASMCs, solutions were adapted from a previous study 73: pipette (internal) 
solution (in mmol/L) contained: 135 K-methanesulphonate, 20 KCl, 2 Na2ATP, 1 MgCl2, 1 
EGTA, 20 HEPES, adjusted to pH 7.2 with KOH.  Bath (extracellular) solution (in mmol/L) 
contained: 140.5 NaCl, 5.5 KCl, 1.5 CaCl2, 1 MgCl2, 10 glucose, 0.5 Na2HPO4, 0.5 KH2PO4, 
10 HEPES, adjusted to pH 6.4, 7.4, or 8.4 with NaOH.  
 
In COS7 cells and hPASMCs, solutions at pH 5.0 contained 10 mmol/L 2-(N-morpholino)ethane 
sulfonic acid instead of HEPES. Solutions at pH 10.4 contained 10 mmol/L Tris-Base instead of 
HEPES.  
 
Voltage Clamp Analysis 
Cell capacitance values were recorded for individual cell recordings, and whole cell currents were 
normalized to cell capacitance (pA/pF) where indicated. Measurements of current for drug analysis 
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(ONO-RS-082, ML365, and ruthenium red) were taken at -50mV to minimize contributions from 
background cellular ionic currents. This was performed by taking the mean current at -50mV over 
an approximately 5 millisecond range centered around -50mV, from the average of 2 to 6 
consecutive traces based on stability of the recording. Measurements of current were taken at 
+60mV for pH experiments (as previously shown in 3), by calculating the mean current during the 
last ~5 milliseconds of the trace, based on the average of 2 to 6 consecutive traces depending on 
stability of the recording at each pH value.  
 
Leak subtraction was manually performed on all recordings in this study. Based on the Nernst 
equilibrium potential for potassium (EK) close to -80mV, negative current values recorded at the 
holding potential of -80mV were designated as leak current, and a proportional amount of leak 
current was extrapolated across the voltage ramp range; an assumption applied for analysis given 
the virtually voltage-independent properties of the KCNK3 and KCNK9 channels. Hence, analysis 
of mean current in any drug condition at -50mV required adding 5/8 of the value of the leak current 
at -80mV to the mean current value recorded at -50mV, and analysis of mean current at +60mV 
required subtracting 6/8 of the value of the leak current at -80mV from the mean current value 
recorded at +60mV.  
 
Current Clamp Analysis 
Measurements of membrane potential were taken as the mean from the last ~10 seconds in any 
given pH or drug condition. To standardize drug analysis, all ONO membrane potential 
measurements were taken from the last ~10 seconds of five minutes of ONO application, and all 
ONO+ML365 membrane potential measurements were taken from the last ~10 seconds of two 
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minutes of ONO+ML365 application. Using pClamp software, a 50X data reduction of recordings 
was performed for data transfer compatibility to Origin software for figure purposes. Data analysis 
was performed on raw data only. 
 
Statistical Analyses 
Graphic analysis was performed with Origin 7.0 and 9.0 (Microcal Software, Northampton, MA). 
pClamp 10 software was used for analysis of raw electrophysiological recordings. Data are 
reported as means ± SEM, based on n observations. Student’s t tests and one-way ANOVA with 
post-hoc Tukey tests were applied as indicated, and significant differences were determined based 





Functional characterization of KCNK3 variants identifies a unique acid sensing phenotype 
We previously identified six loss of function mutations in KCNK3 causing PAH.55 Given the 
extreme sensitivity of KCNK3 channels to extracellular pH changes within the physiological pH 
range, here we investigated the mechanistic basis of loss of channel function focusing on possible 
mutation-induced changes in the pH dependence of the expressed channels. Wildtype (WT) or 
mutant KCNK3 channels were expressed in COS7 cells, and a whole-cell voltage ramp was 
applied across a physiological voltage range (Figure 1.1A, top). As expected for WT KCNK3 
channels, we observed appreciable K+ current at physiological extracellular pH 7.4; inhibition of 




Compared to WT KCNK3 channels, all six PAH-associated mutant KCNK3 channels exhibited 
loss of function at pH 7.4 and pH 10.4 (Figure 1.1B), with one notable exception: V221L KCNK3 
conferred loss of function at physiological pH 7.4, with recovery of function observed at alkalotic 
pH 10.4 (Figure 1.1A and 1.1B). Given its unique alteration in pH dependent regulation of activity, 
V221L KCNK3 was tested in more physiologic conditions to understand the consequence of 
dysfunction on channel regulation and pharmacology.  
 
Figure 1.1 PAH-associated mutant KCNK3 
channels demonstrate mutation-specific severity 
of loss of function, across a broad pH range in 
COS7 cells. A, Typical voltage clamp recordings 
of WT (top) and V221L (bottom) KCNK3. 
Sample current traces at pH 6.4 (blue), 7.4 
(black), and 10.4 (red) are shown. A voltage 
ramp (top) was applied, -120mV to +60mV over 
0.5s, every 3 seconds, from a holding potential 
of -80mV for all voltage clamp recordings in this 
study. B, Summary of current density (pA/pF at 
60mV) of cells expressing WT or one of the 
PAH-associated mutant KCNK3 channels (n=3 
to 9 cells at pH 6.4; n= 6 to 33 cells at pH 7.4; 
n= 6 to 32 cells at pH 10.4). Bars show mean ± 
SEM. * indicates p<0.05 at pH 7.4; # indicates 
p<0.05 at pH 10.4, for the comparison of WT 
and each KCNK3 mutant channel by one-way 
ANOVA and post-hoc Tukey test.  
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Cultured hPASMCs provide a physiological platform for KCNK3 expression 
KCNK3 currents contribute to the resting potential of native PASMCs, and the downregulation or 
inhibition of KCNK3 causes PASMC depolarization, excessive proliferation, and pulmonary 
arterial constriction.73-75,88 Cultured PASMCs have been employed previously to study 
overexpressed potassium channel activity, regulation, and pharmacology in the context of 
PAH.81,85 We adapted this approach to test the hypothesis that both WT and mutant (eg. V221L) 
KCNK3 channels represent therapeutic targets in PAH (Figure 1.2).   
 
As loss of function could result from lack of KCNK3 expression, we first engineered a C-terminal 
GFP-tagged KCNK3 channel (KCNK3-GFP, Figure 1.2A) and screened its function in COS7 
cells. We observed a similar pH dependence for KCNK3-GFP versus KCNK3, as well as a 
significant increase in current density (pA/pF, measured at 60mV) for KCNK3-GFP (Figure 1.2B). 
In voltage clamp experiments, ONO 10µM activated KCNK3-GFP with similar efficacy to 
KCNK3 channels (Figure 1.2C; and compare to KCNK3 activation previously reported55). The 
recently developed KCNK3 inhibitor, ML365 10µM,158,159 produced robust inhibition of KCNK3-
GFP currents (Figure 1.2C). Mean current densities (pA/pF) in response to the drugs are 
summarized in Figure 1.2C, measured at -50mV to minimize interference of background ionic 
currents.  
 
The use of KCNK3-GFP thus did not appreciably change KCNK3 function or pharmacology, 
while providing the advantage of increased current density. Next, KCNK3-GFP was expressed in 
cultured hPASMCs, identified by green fluorescence, and produced similar current density (pA/pF 
at 60mV) compared to KCNK3-GFP expression in COS7 cells (Figure 1.2D). 
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Loss of native KCNK3 expression was previously demonstrated in cultured PASMCs,32 and 
confirmed functionally in our system of cultured hPASMCs by applying ML365 10µM in non-
transfected hPASMCs, and observing no significant effect on cell currents (Figure 1.2E and 1.2F, 
and Figure 1.3B). In comparison, KCNK3-GFP expression in hPASMCs produced robust channel 
activity, inhibited by ML365 10µM (Figure 1.2G and 1.2H, and Figure 1.3B and 1.3C). We thus 
developed a platform to compare the relative impact of expressed mutant versus WT KCNK3 
channels on hPASMC membrane potential, and the effect of KCNK3 pharmacological agents in a 

















Figure 1.2. KCNK3 expression platform in human pulmonary artery smooth muscle cells 
(hPASMCs). A, KCNK3, tagged with GFP at the C-terminus, was engineered (KCNK3-GFP). 
B, KCNK3-GFP is activated by ONO-RS-082 10uM (red trace, left) and inhibited by ML365 
10uM (blue trace, right), under voltage-clamp shown in COS7 cells. Pre-drug (control, black 
traces) and drug conditions are at pH 7.4. Bar graphs (bottom) show fold change in current at -
50mV after ONO (n=8 cells) or ML365 (n=12 cells) application. C, Cultured hPASMCs 
expressing KCNK3-GFP fluoresce green (top, right). Bar graph shows KCNK3-GFP current 
activity at pH 7.4 (pA/pF at 60mV) in hPASMCs (grey, n=20 cells) versus COS7 cells (black, 
n=26 cells). D Background hPASMC current at pH 7.4 (control, grey trace), and current in 
ML365 10uM (blue trace) are shown. E, Sample ML365 time course of action in control and 
drug conditions, measured at -50mV, from a starting current amplitude of -6pA indicated by the 
arrow. F, Current from hPASMC expressing KCNK3-GFP is shown at pH 7.4 (control, grey 
trace), and in ML365 10uM (blue trace). G, Sample ML365 time course of action in control and 
drug conditions, measured at -50mV, from a starting current amplitude of 412 pA indicated by 
the arrow. Horizontal dashed line is drawn at the starting level of current in control solution. Bar 
graphs show mean ± SEM. * indicates p<0.05 by the paired (panel B) and unpaired (panel C) 
Student’s t test. 
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Figure 1.3.  KCNK3-GFP expression and activity in hPASMCs. A, Summary of current clamp 
results of KCNK3-GFP expressed in hPASMCs, with mean membrane potentials (mV) measured 
at pH 6.4 (blue), pH 7.4 (black), and pH 10.4 (red) shown (n=2 to 4 cells per pH value). B, 
Comparison of the ML365-sensitive current (pA/pF at -50mV, pH 7.4), in hPASMCs expressing 
KCNK3-GFP (n=3 cells) versus no transfection (n=6 cells). C, Gradient of current expression 
(pA/pF at 60mV, pH 7.4) in hPASMCs expressing KCNK3-GFP (n=20 cells), V221L KCNK3-
GFP (n=7 cells), and GFP only (n=3 cells). D, Sample current trace of V221L KCNK3-GFP in 
hPASMC at pH 7.4 (black) and pH 8.4 (red). E, Summary of V221L KCNK3 expression in COS7 
cells versus V221L KCNK3-GFP expression in hPASMCs (n=4 to 7 cells per lane), showing 
greater current activity of expressed channels in hPASMCs (pA/pF at 60mV, pH 7.4 in black, pH 
8.4 in red). Data are represented as means ± SEM. * indicates p<0.05 by the unpaired Student’s t 







Figure 1.4. Robust response of KCNK3 channels to pH changes and pharmacological 
modulators in hPASMCs. A, Voltage clamp recording of KCNK3-GFP expressed in hPASMCs 
at pH 6.4 (blue), pH 7.4 (black), and pH 10.4 (red). B, KCNK3-GFP expression in hPASMCs 
(grey curve) versus COS7 cells (black curve) across a broad pH range, with current normalized 
to max current at pH 10.4 (n =9 to 12 cells per pH data point in COS7; n=2 to 6 cells per pH 
data point in hPASMCs; fitted by the Hill equation). C, Current clamp recording of WT 
KCNK3-GFP, with changes in membrane potential (mV) measured at pH 6.4 (blue), pH 7.4 
(black), and pH 10.4 (red). D, Current clamp recording of WT KCNK3-GFP (red trace), 
showing changes in membrane potential (mV) upon application of ONO, ONO+ML365, or pH 
8.4. E, Current clamp recording of V221L KCNK3-GFP (blue trace), showing changes in 
membrane potential (mV) upon application of ONO, or ONO+ML365. F, Current clamp 
summary of WT (red) and V221L (blue) KCNK3-GFP for resting potential, ONO, and 
ONO+ML365 conditions (n=3 to 11 cells per condition). Data plots represent means ± SEM. * 
indicates p<0.05 by the unpaired Student’s t test; N.S. indicates no significant difference.  
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Activation of PAH-associated mutant KCNK3 channels in hPASMCs 
KCNK3-GFP expression in hPASMCs produced a consistent pH dependence of expressed channel 
activity compared to expression in COS7 cells (Figure 1.4A and 1.4B). We recorded membrane 
potentials in cells expressing KCNK3-GFP at physiological pH 7.4, upon channel activation by 
pH 10.4, and upon inhibition by pH 6.4. A sample current clamp trace (Figure 1.4C) reveals a 
resting potential of -68mV at pH 7.4, hyperpolarization to -70mV at pH 10.4, and depolarization 
to -44mV at pH 6.4 (summarized above in Figure 1.3A).  
 
Next, we determined the relative impact of pharmacological activation and inhibition of KCNK3 
in hPASMCs expressing WT or V221L KCNK3-GFP. A recording of a cell expressing WT 
KCNK3-GFP (Figure 1.4D), demonstrates a resting potential of -62mV at physiological pH 7.4; 
hyperpolarization by ONO 10µM to -73mV; and depolarization to -51mV upon co-application of 
ML365 10µM. By comparison, a recording of a cell expressing V221L KCNK3-GFP (Figure 
1.4E), reveals a resting potential of -40mV at physiological pH 7.4; hyperpolarization by ONO 
10µM to -61mV; and depolarization to -33mV upon co-application of ML365 10µM. A summary 
of resting potentials, and responses to ONO 10µM, and to ML365 10uM, is shown in Figure 1.4F, 
for WT and V221L KCNK3-GFP. In each condition, V221L KCNK3-GFP responses are 







KCNK3 heterodimeric channels are functional reporters of KCNK3 heterozygosity 
After demonstrating that PAH-associated mutant KCNK3 channels are potential therapeutic 
targets in hPASMCs, we investigated the consequence of heterozygosity on channel function more 
closely. All patients harboring PAH-associated KCNK3 mutations in our study are heterozygous 
at the KCNK3 locus, possessing one mutant and one WT KCNK3 channel subunit.55 KCNK3 is 
known to dimerize, forming functional channels from two subunits joined together.156 For 
heterozygous expression, net current is therefore a result of three populations of channels: 
homodimers of WT or mutant KCNK3, and heterodimers with one of each subunit. To fully 
characterize the impact of the KCNK3 mutations in clinically relevant heterozygous conditions, 
we engineered tandem-linked KCNK3 dimers by joining two KCNK3 subunits with a glycine-rich 
linker. By forcing assembly of mutant and/or WT KCNK3 subunits to one another, we assessed 
function of discrete proportions of channels that form in a heterozygous patient (Figure 1.5).  
 
We tested function of mutant heterodimeric channels containing the V221L mutation. Figure 1.5A 
and 1.5B depict the engineered WT KCNK3 homodimer and WT-V221L mutant KCNK3 
heterodimer, respectively, with sample current traces shown at extracellular pH 6.4, 7.4, and 10.4 
from voltage clamp experiments. Figure 1.5C summarizes current density measurements (pA/pF 
at 60mV) for each dimer. Significant loss of function was observed at pH 7.4 for WT-V221L 
heterodimeric channels.  We recorded V221L-containing KCNK3 function over a broad pH range, 
5.0 through 10.4, and notably, WT-V221L KCNK3 produced an intermediate rightward shift in 
pH dependence (Figure 1.5D, blue curve), with intermediate channel activity at physiological pH 
7.4, compared to WT KCNK3 (Figure 1.5D, black curve), and V221L KCNK3 (Figure 1.5D, red 
curve), for which we observed an extreme rightward shift in pH dependence. 
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The dominant-negative impact of KCNK3 heterozygosity on channel function was quantified 
further, as we observed that the linked heterozygous WT-V221L KCNK3 dimers produce more 
consistent channel function than co-expression assays of WT+V221L KCNK3 channels. Figure 
1.5E shows a scatterplot of individual voltage clamp recordings (n=16 to 33 cells per condition: 
WT, V221L, WT-V221L heterodimer, and WT+V221L co-expression), with each data point 
representing the current recorded at physiological pH 7.4, normalized to maximal current at pH 
10.4, measured at 60mV. Loss of function was observed for all conditions containing V221L 
mutant channels (homomeric V221L, WT-V221L heterodimer, and co-expression of WT + 
V221L). Importantly, we observed greater variation in current when co-expressing WT + V221L 
channels compared to WT-V221L heterodimer expression, as the co-expression population 














Figure 1.5. Tandem-linked KCNK3 heterodimeric channels are functional reporters of KCNK3 
heterozygosity. A and B, KCNK3 dimers were engineered by interconnecting two KCNK3 
subunits with a glycine-rich linker. The WT KCNK3 homodimer (panel A) and the WT-V221L 
KCNK3 heterodimer (panel B) are depicted, with sample voltage clamp recordings for each 
condition. Current traces at pH 6.4 (blue), 7.4 (black), and 10.4 (red) are shown. C, Summary of 
current densities (pA/pF at 60mV) at pH 6.4, 7.4, and 10.4 (n= 4 to 16 cells per pH bar). D, KCNK3 
current activity is depicted for WT (black curve), V221L (red curve), and WT-V221L heterodimer 
(blue curve), at extracellular pH 5.0 through 10.4, with current normalized to max current at pH 
10.4 (n= 5 to 33 cells per pH value plotted; fitted by the Hill equation). E, Scatterplot of current at 
pH 7.4 normalized to current at pH 10.4, for WT, V221L, WT-V221L heterodimer, and WT + 
V221L co-expression. Each dot represents an independent cell recording. Mean current in each 
condition is displayed at the horizontal line (n=16 to 33 cells per condition, measured at 60mV). 
Bar graphs and pH curve values show means ± SEM. * indicates p < 0.05 for the comparison of 
WT versus WT-V221L KCNK3 dimer conditions in panel C by the unpaired Student’s t test; In 
Panel E, p < 0.05 for the comparison of all KCNK3 conditions, calculated by one-way ANOVA 
and post-hoc Tukey test.  
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Pharmacological activation of heterodimeric mutant KCNK3 channels  
In voltage clamp recordings, WT KCNK3 homodimers (Figure 1.6A) and WT-V221L mutant 
heterodimers (Figure 1.6B) were activated by ONO 10µM (shown in red), and inhibited by ML365 
10µM (shown in blue), in voltage clamp recordings. PAH-associated KCNK3 heterodimeric 
channels thus represent therapeutic targets in PAH, susceptible to pharmacological recovery. 
Patients with PAH due to heterozygous KCNK3 mutation therefore possess a significant proportion 
of assembled KCNK3 channels (wildtype and mutant) that, dependent on the mutation, represent 
viable targets for treatment. 
 
As shown previously,55 cells expressing T8K or E182K KCNK3 channels are modulated by ONO 
10µM. Importantly, ONO is not a KCNK3-specific activator and produces variable responses in 
the presence and absence of KCNK3; as such, it is difficult to quantify the drug’s effect, especially 
in the setting of loss-of-function KCNK3 mutant channels that produce small currents at baseline 
(Figure 1.7A-C).  
 
In addition to the WT-V221L KCNK3 heterodimer, the WT-E182K KCNK3 heterodimer responds 
robustly to current activation by ONO 10µM, suggesting that a significant population of channels 
(wildtype and mutant heterodimeric) in patients with heterozygous KCNK3 mutations respond to 










Figure 1.6. Wildtype (WT) and mutant KCNK3 
dimers respond to pharmacological modulation. A, 
WT KCNK3 dimer (top) is activated by ONO-RS-
082 10uM (red trace) and inhibited by ML365 
10uM (blue trace), in current recordings from 
voltage clamp experiments. Control (pre-drug, pH 
7.4) traces are shown in black. Bar graphs show 
fold change in current at -50mV for the WT 
KCNK3 dimer, after ONO (red, n=4 cells) or 
ML365 (blue, n=7 cells) application. B, WT-
V221L KCNK3 heterodimer (top) is activated by 
ONO-RS-082 10uM (red trace), and inhibited by 
ML365 10uM (blue trace), and heterodimer 
channel activity was confirmed by channel 
activation at extracellular pH 10.4 (grey dotted 
traces). Control (pre-drug, pH 7.4) traces are shown 
in black. Bar graphs show fold change in current at 
-50mV for the WT-V221L heterodimer, after ONO 
(red, n=5 cells) or ML365 (blue, n=3 cells) 
application. Bar graphs display mean ± SEM. * 









Figure 1.7. ONO-RS-082’s effect on homomeric and heterodimeric mutant KCNK3 
channels associated with PAH. Voltage clamp recordings in COS7 cells are depicted. A-D, 
The effect of ONO-RS-082 10 µM (red traces) at extracellular pH 7.4 on currents from cells 
expressing T8K KCNK3 (A); V221L KCNK3 (B); E182K KCNK3 (C); and heterodimeric 
WT-E182K KCNK3 (D). Control (pre-drug) conditions at extracellular pH 7.4 (black traces) 
are shown for each recording.  
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KCNK3 and KCNK9 form functional heterodimeric channels 
To elucidate the broader impact of KCNK3 heterozygosity on channel function, we investigated 
the interactions of KCNK3 with a closely related acid-sensitive, two-pore domain potassium 
channel, KCNK9 (Figure 1.8A, top). Previous reports have shown that KCNK3 heterodimerization 
with KCNK9 results in functional channels consisting of one KCNK3 subunit and one KCNK9 
subunit.103,106-108,111 We engineered the first known tandem-linked human KCNK9-KCNK3 
heterodimer (Figure 1.8B, top). 
  
The true dimeric assembly of KCNK9 with KCNK3 to form KCNK9-KCNK3 heterodimers was 
confirmed by ruthenium red (RR) sensitivity analysis: KCNK9 was previously shown to be 
inhibited by RR (10µM), while KCNK9-KCNK3 heterodimers and KCNK3 channels were not 
inhibited by RR 10µM as KCNK3-containing channels lack a necessary glutamic acid residue 
(E70) for RR binding and channel pore block.103 Figure 1.8A (bottom) shows inhibition of KCNK9 
currents by RR 10µM at pH 7.4, and Figure 1.8B (bottom) shows no effect by RR 10µM on 
KCNK9-KCNK3 heterodimer currents. Sample drug time courses are shown in Figures 1.8C and 
8D, for KCNK9 and KCNK9-KCNK3, respectively; RR sensitivity data are summarized in Figure 
8G, for KCNK9, KCNK3, and KCNK9-KCNK3 (and see Figure 1.9A-C).  
 
After verifying the formation and expression of the KCNK9-KCNK3 tandem dimer, we evaluated 
the pH dependence of KCNK9-containing channels. KCNK9 has a left-shifted pH dependence 
profile compared to KCNK3, rendering it more maximally activated at physiological pH 7.4 
(Figure 1.8E, and compare with Figure 1.1A). We observed increased K+ current activity at pH 
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7.4 for KCNK9-KCNK3 compared to KCNK3 homomeric channels, as expected (Figure 1.8F, 
























Figure 1.8. KCNK9 forms functional heterodimers with KCNK3.  A, The effect of 
ruthenium red (RR) 10uM (red trace) on KCNK9 channels. Control trace (pre-drug, pH 
7.4) shown in grey. B, The effect of RR 10uM (red trace) on KCNK9-KCNK3 
heterodimeric channels. Control trace (pre-drug, pH 7.4) shown in grey. C, Sample RR 
time course of action on KCNK9 in control and drug conditions, measured at -50mV, from 
a starting current amplitude of 1682 pA indicated by the arrow. Horizontal dashed line is 
drawn at the starting level of current in control solution. D, Sample RR time course of 
action on KCNK9-KCNK3 heterodimers in control and drug conditions, measured at -
50mV, from a starting current amplitude of 18 pA indicated by the arrow. E, Voltage clamp 
recording of KCNK9. F, Voltage clamp recording of KCNK9-KCNK3. For E and F, 
sample current traces at pH 6.4 (blue), 7.4 (black), and 10.4 (red) are shown. G, Summary 
of RR’s effect on KCNK9, KCNK3, and KCNK9-KCNK3, measured by fold change in 
current at -50mV (n=5 to 8 cells per condition). H, Summary of mean current at pH 7.4 
normalized to current at pH 10.4, measured at 60mV, for KCNK9, KCNK3, and KCNK9-
KCNK3 (n=10 to 25 cells per condition). Bar graphs show mean ± SEM. * indicates 
p<0.05 by the paired Student’s t test for the comparison of control versus ruthenium red 
conditions (panel G), and * indicates p<0.05 by one-way ANOVA and post-hoc Tukey 
test for the comparison of KCNK9, KCNK3, and KCNK9-KCNK3 (panel H). 
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Figure 1.9. A, The effect of ruthenium red (RR) 10 µM (red trace) on KCNK3 channels in 
COS7 cells is shown. Control trace (pre-drug, pH 7.4) is depicted in grey. B, Sample RR time 
course of action on KCNK3 in control and drug conditions, measured at -50mV, from a starting 
current amplitude of 196 pA indicated by the arrow. C, RR’s effect on KCNK9, KCNK3, and 
KCNK9-KCNK3 channels is summarized, showing fold change in current at -50mV (n=5 to 8 
cells per condition). D, Quantitative real-time PCR analysis of human lung samples from 
healthy (Control) and congenital cardiac defect-associated PAH (APAH) patient lungs. 
Expression of KCNK3 (black bars), and KCNK9 (grey bars) are compared, based on mean 
cycle threshold (Ct) values observed for each gene; Ct > 35 indicates no quantifiable gene 
expression (n=5 patient lungs for each lane). Bars shown mean ± SEM. E, Fold difference in 
KCNK3 gene expression, calculated by the 2-ddCt method, in FPAH and APAH versus Control 
patient lungs. No significant (N.S.) fold changes were observed compared to control. F-G, Co-
expression of KCNK9 with WT KCNK3 channels (panel F), and KCNK9 with V221L KCNK3 
channels (panel G) with sample voltage clamp recordings shown for each condition at pH 6.4 
(blue), pH 7.4 (black) and pH 10.4 (red). H, Summary of current activity for co-expression of 
KCNK9 with WT KCNK3 (left) versus V221L KCNK3 (right). Current at pH 6.4 (blue) and 
pH 7.4 (black) is normalized to max current at pH 10.4 (n=5 to 8 cells per lane). Experiments 
were performed in COS7 cells. Bar graphs show mean ± SEM. * indicates p<0.05 by the paired 
Student’s t test for the comparison of control versus ruthenium red conditions in panel C; * 
indicates p<0.05 by the unpaired Student’s t test in panel H.  
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KCNK3, but not KCNK9, is expressed in healthy and PAH patient lungs 
KCNK9 is thought to be co-expressed with KCNK3 in various tissues outside of the lung, including 
in the central nervous system, heart, and adrenal glands, and functional heterodimerization of 
KCNK3 with KCNK9 in multiple tissues has already been studied.89,100,103,108,111 KCNK3 is 
expressed in hPASMCs, while KCNK9 has been reported absent from hPASMCs.73 We performed 
gene expression analysis on whole human lung tissue samples from healthy (control) subjects, and 
from patients with familial pulmonary arterial hypertension (FPAH). KCNK3 expression was 
observed in lungs of control and FPAH patients, while no quantifiable expression of KCNK9 was 
observed in control or FPAH patient lungs (Figure 1.10A, top; and see Figure 1.9D and 1.9E). 
Therefore, of all possible KCNK3/KCNK9 channel combinations, only KCNK3 homomeric 
channels would be expected to form in human lung tissue (Figure 1.10A, bottom).  KCNK9-
KCNK3 heterodimerization adds to the complexity of KCNK3 activity, particularly in PAH 













Figure 1.10. KCNK9 protects against KCNK3 dysfunction. A, Quantitative real-time PCR 
analysis of human lung samples from healthy (Control) and familial PAH (FPAH) patient lungs. 
Expression of KCNK3 (black bars), and KCNK9 (grey bars) are compared, based on mean cycle 
threshold (Ct) values observed for each gene; Ct > 35 indicates no quantifiable gene expression 
(n=5 patient lungs for each lane). Of the possible KCNK3 + KCNK9 channel combinations, 
only KCNK3 homomeric channels (boxed, left) are predicted to form in human lungs. B, 
Voltage clamp recordings of the WT-G203D KCNK3 heterodimer (left), and the KCNK9-
G203D KCNK3 heterodimer (right), showing current traces at pH 6.4 (blue), 7.4 (black), and 
10.4 (red). C, Summary of current densities (pA/pF at 60mV) at pH 6.4, 7.4, and 10.4 (n= 4 to 
14 cells per pH bar). Bar graphs show mean ± SEM. * indicates p<0.05 by the unpaired 
Student’s t test. 
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KCNK9 protects against KCNK3 dysfunction 
The lung-specific disease phenotype in patients with heterozygous KCNK3 mutation, despite 
widespread tissue expression of KCNK3, remains a puzzling phenomenon: are lungs particularly 
susceptible to KCNK3 loss of function due, in part, to the absence of KCNK9? We sought to 
determine whether KCNK9 can recover function of even the severe mutant G203D KCNK3 
channel, in order to test the hypothesis that co-assembly of KCNK9 with KCNK3 provides 
protection against heterozygous KCNK3 mutation when the channels are co-expressed, while the 
absence of KCNK9 in the lungs underlies the lung-specific phenotype in the setting of 
heterozygous KCNK3 loss of function.  
 
G203D KCNK3 disrupts the conserved “GxG” potassium selectivity filter amino acid sequence in 
one of the channel’s two pore-loop domains, a region sensitive to dominant-negative 
mutations.133,160,161 We first engineered and studied the WT-G203D KCNK3 heterodimer (Figure 
10B, left), and indeed observed severe dominant-negative dysfunction, as the mutant channels 
produced small currents across pH 6.4 through 10.4 (Figure 1.10B and 1.10C; also see Figure 
1.11). 
 
Next, we engineered a KCNK9-G203D KCNK3 mutant heterodimer to determine the impact of 
KCNK9 assembly with G203D KCNK3 (Figure 1.10B, right). We observed appreciable pH-
sensitive currents, with significantly increased current density at physiological pH 7.4 and pH 10.4, 
compared to WT-G203D KCNK3 heterodimeric channels (Figure 1.10B and 1.10C). KCNK9 thus 
assembles with mutant KCNK3 channels to produce functional recovery and provide protection 
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against KCNK3 channel dysfunction (see also Figure 1.9F-H for modelling heterozygous co-





Figure 1.11. KCNK3 heterodimeric GFP fusion dimer confirms the more severe loss of 
function in G203D versus V221L-containing KCNK3 channels. A, A WT-G203D KCNK3-
GFP fusion heterodimer was engineered by interconnecting two KCNK3 subunits with a 
glycine-rich linker, and inserting a C-terminal GFP tag. Given the relative severity of G203D 
KCNK3 dysfunction, the GFP fusion construct ensured channel expression in fluorescent cells 
studied. Sample traces from a voltage clamp recording are shown at extracellular pH 5 (blue), 
pH 7.4 (black), and pH 10.4 (red), revealing small currents across the pH range. B, Summary 
of current densities (pA/pF at 60mV) at pH 5 (blue), pH 7.4 (black), and pH 10.4 (red) for the 
WT-V221L KCNK3 heterodimer versus the WT-G203D KCNK3-GFP heterodimer (n= 6 to 
16 cells per pH bar). Bars show mean ± SEM. * indicates p<0.05 at pH 7.4 and pH 10.4, by the 




Our initial characterization of KCNK3 mutations associated with PAH showed loss of function for 
all disease-associated mutant channels.55 Here, we have reported five major findings, summarized 
schematically in Figure 1.12. First, KCNK3 mutations associated with PAH harbor mutation-
specific severity of loss of function that can occur by distinct underlying mechanisms. Second, 
mutant and WT KCNK3 channels can be pharmacologically activated in hPASMCs to cause 
membrane hyperpolarization, and thus represent potential targets for PAH treatment. Third, mutant 
heterodimeric tandem-linked KCNK3 channels provide a valuable tool for evaluating the 
functional impact of clinically relevant heterozygous KCNK3 conditions, as they report function 
of a substantial, discrete proportion of formed KCNK3 channels in heterozygous patients. Fourth, 
mutant heterodimeric KCNK3 channels can be pharmacologically targeted for activation, 
dependent on the mutation. Fifth, KCNK9 co-expression and assembly with KCNK3 channels 
protects against KCNK3 dysfunction, which we hypothesize contributes to the lung-specific 












Figure 1.12. Schematic of the proposed impact of heterozygous potassium channel subfamily 
K member 3 (KCNK3) mutation in pulmonary arterial hypertension (PAH). Wildtype KCNK3 
(light blue) and mutant (“PAH”) KCNK3 (dark blue) homomeric, and heterodimeric channels 
are expressed in human lung. Additional interactions of KCNK3 with KCNK9 (brown) channel 
subunits occur outside of the lung, protecting against KCNK3 loss of function. However, in 
pulmonary artery smooth muscle cells (hPASMCs), only KCNK3 (and not KCNK9) is 
expressed, and the greater proportion of mutant KCNK3 channels in hPASMCs promotes 
membrane depolarization. ONO-RS-082, a KCNK3 activator, recovers function of some 
mutant and wildtype KCNK3 channels leading to PASMC hyperpolarization, which may 
represent a therapeutic avenue in PAH. 
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A unique pH-dependent mechanism of mutant KCNK3 channel dysfunction in PAH 
 
Potassium channel mutations confer loss of function by discrete mechanisms of varying severity. 
In well-studied channelopathies, mechanisms of dysfunction include defects in trafficking, channel 
assembly, and electrophysiological function, dependent on the location of the mutation.162,163  
 
In our study, V221L KCNK3 confers a pH-dependent mechanism of loss of function. Extracellular 
histidine residues lining the KCNK3 channel pore account for nearly all of the pH sensitivity of 
KCNK3 directly, as protonation of these residues leads to inhibition of potassium 
conductance.156,164 However, other regions, including the extracellular portion of the fourth 
transmembrane segment of KCNK3 – the location of the V221 residue - may contribute to pH 
sensing and channel inhibition indirectly by stabilizing the channel pore and the selectivity filter 
within it.99,164 The unique properties of V221L KCNK3 can be exploited for KCNK3 structure-
function studies in relation to the channel’s crucial regulation by pH. 
  
Mutant and wildtype KCNK3 channels are pharmacological targets in hPASMCs 
Potassium channels regulate the resting membrane potential of pulmonary artery smooth muscle 
cells.60,70,126 Voltage-gated potassium channels are involved in the hypoxic pulmonary 
vasoconstrictive response,165 while downregulation of Kv channel expression in PASMCs of PAH 
patients promotes PASMC excitability and proliferation, and excessive pulmonary arterial 
vasoconstriction.80,81,166 Potassium channel openers may provide therapeutic benefit by opposing 
such deleterious pulmonary arterial remodeling;167 recently, pharmacological KCNK3 activation 
by ONO-RS-082 (ONO) attenuated development of pulmonary hypertension in a monocrotaline-
induced rat model.55,75 
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We therefore studied mutant and WT KCNK3 activation in human PASMCs. KCNK3 expression 
is nearly completely lost in cultured PASMCs, as a proliferative versus contractile smooth muscle 
cell phenotype predominates concomitant with loss of potassium channel expression and cell 
depolarization.32 Previous studies have employed anandamide and A293, inhibitors of KCNK3 
channel activity, to analyze the functional contributions of KCNK3 on hPASMC 
excitability.75,88,112,168 We confirmed loss of native KCNK3 channel activity in cultured hPASMCs 
using a recently developed, more selective KCNK3 inhibitor, ML365 (Figure 1.2E-H and Figure 
1.3B.158  
 
We exploited the properties of cultured hPASMCs to compare the relative impact of expressed 
mutant versus WT KCNK3 channels in a more physiological environment. The current clamp 
results in Figure 1.4 demonstrate that (1) a gradient exists for the relative contribution of mutant 
and WT KCNK3 to the resting potential of hPASMCs, with cells expressing mutant KCNK3 more 
depolarized at rest; and (2) activation of mutant or WT KCNK3 by ONO hyperpolarizes 
hPASMCs, highlighting PAH-associated mutant and WT KCNK3 channels as viable 
pharmacological targets. Given the over-expression of KCNK3 in our system, the results are not 
meant to suggest that the magnitude of membrane voltage responses is physiological, but rather 
provide proof of principle for the graded responses of mutant and WT KCNK3 channels to 
pharmacologic activation in hPASMCs. 
 
Based on the variable time course of activation of KCNK3 by ONO (seconds to minutes, not 
instantaneous), we hypothesize that ONO does not bind directly to the channel. More likely, ONO 
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acts on membrane phospholipase pathways to alter KCNK3 phosphorylation. It has been shown 
that phospholipase C (PLC) activation leads to KCNK3 inhibition,168 and endothelin-1, a 
vasoconstrictor and mediator of PAH pathogenesis, inhibits KCNK3 in hPASMCs leading to 
depolarization, the sensitivity of which requires endothelin-A receptors, PLC, phosphatidylinositol 
4,5-bisphosphate (PIP2), diacylglycerol (DAG), and protein kinase C.169 Activation of endothelin 
receptors was shown to cause KCNK3 phosphorylation via rho kinase activation,170 and DAG was 
recently identified as a direct regulator of KCNK3 downstream of activated G protein-coupled 
receptors.171 Ultimately, elucidating the specific pathways involved in KCNK3 activation by ONO 
will further cultivate KCNK3 activation as a PAH treatment paradigm.172  
 
Mutant KCNK3 heterodimeric channel function and recovery 
Mature KCNK3 channels dimerize, forming functional channels from two individual KCNK3 
subunits that co-assemble.156 In this study, tandem-linked KCNK3 heterodimers served as a 
functional reporter of a discrete and substantial population of formed channels in heterozygous 
patients. The dominant-negative phenotype conferred by the V221L KCNK3 mutation did not 
prevent pharmacological recovery of function: heterodimeric WT-V221L KCNK3 channels 
responded to pharmacological activation by ONO. As KCNK3 downregulation occurs in PAH 
irrespective of a patient’s KCNK3 genetic status,75 KCNK3 activation indeed represents a more 
generalizable therapeutic approach in pulmonary hypertension due to any cause. 
  
While appreciable activation of homomeric mutant channels with marked loss of function at 
baseline was difficult to discern, we have demonstrated robust current activation of mutant 
heterodimeric KCNK3 channels by ONO (Figure 1.6; and see Figure 1.7). Thus, in PAH patients 
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heterozygous at the KCNK3 gene locus, the majority of formed channels – the combination of WT 
homodimeric and mutant heterodimeric KCNK3 channels – may respond markedly to 
pharmacological activation and represent targetable therapeutic substrates.  
 
KCNK9 minimizes the impact of KCNK3 loss of function 
Interestingly, none of the PAH patients in our cohort with heterozygous KCNK3 mutations 
possessed a primary clinical phenotype outside of the lung, despite widespread KCNK3 expression 
in the body.97 KCNK9, which has been shown to heterodimerize with KCNK3,103 is absent from 
human lungs of healthy controls and PAH patients (Figure 1.10A; and see Figure 1.9D and 1.9E), 
but assembles with KCNK3 in tissues where both KCNK9 and KCNK3 are expressed, leading to 
diversity of channel currents.106,108,111 It has been shown that KCNK9 protects against cell stress,173 
and the concept of protection by KCNK9 was extended to our study in the context of KCNK3 
dysfunction. We observed that KCNK9 heterodimerization with WT and G203D KCNK3 
increased current activity at physiological pH 7.4 compared to equivalent KCNK3-only based 
channels. 
 
We hypothesize that the co-expression of KCNK9 with KCNK3 in tissues outside the lung 
provides redundancy of channel function and protection against KCNK3 mutations of varying 
severity, sparing tissues outside the lung of disease. Perhaps the partial loss of KCNK3 function 
outside the lung is alleviated by an upregulation of KCNK9 and/or preferential binding of KCNK9 
with mutant KCNK3 to recover function. Meanwhile, the absence of KCNK9 in the lung would 
leave PASMCs susceptible to excessive depolarization, proliferation, and vasoconstriction in the 
setting of KCNK3 dysfunction.  
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Incomplete penetrance was observed in individuals with PAH-associated KCNK3 mutations.55 
Alongside the mutation-specific severity of KCNK3 dysfunction observed in this study, 
conceivably, KCNK9 provides greater protection in some individuals than others. Some patients 
with heterozygous KCNK3 mutation may develop PAH at a later age of onset, or not develop PAH 
at all, dependent, in part, on KCNK9 channel activity. 
 
Limitations 
The impact of KCNK3 heterozygosity at the pulmonary arterial level remains undetermined. Due 
to its altered pH dependence easily discerned in electrophysiological studies, the V221L KCNK3 
mutation represents a model mutation to incorporate into a rat model (eg. using CRISPR knock-in 
technology) to recapitulate KCNK3 heterozygosity and evaluate the pathophysiological 
consequences in the lungs and outside of them.75,87 
 
Uncovering the cellular pathways involved in KCNK3 activation by ONO has broader 
implications than for PAH pathogenesis and treatment alone. For instance, enhanced KCNK3 
activity was recently demonstrated in atrial myocytes of patients with chronic atrial fibrillation, 
leading to shortening of the action potential duration.174 Mechanistic understanding of ONO’s 
regulation of KCNK3 would aid the development of more selective pharmacological modulators 






We have demonstrated, for the first time, that KCNK3 mutations associated with PAH harbor 
differing underlying mechanisms of loss of function of varying severity; that mutant KCNK3 
channels represent viable therapeutic targets in PAH via activation by ONO-RS-082 in pulmonary 
artery smooth muscle cells; that engineered mutant heterodimeric KCNK3 channels report 
function of a substantial proportion of formed KCNK3 channels in heterozygous patients, and that 
heterodimeric KCNK3 channels can be pharmacologically activated; and lastly, that 
heterodimerization of KCNK9 with KCNK3 can serve a protective role to minimize the impact of 
heterozygous KCNK3 loss of function, which may underlie the PAH-specific phenotype observed 
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Background: In pulmonary arterial hypertension, pathological changes in pulmonary arterioles 
progressively raise pulmonary artery pressure and increase pulmonary vascular resistance, leading 
to right heart failure and high mortality rates. Recently, the first potassium channelopathy in 
pulmonary arterial hypertension, due to mutations in KCNK3, was identified as a genetic cause 
and pharmacological target. 
Methods: Exome sequencing was performed to identify novel genes in a cohort of 99 pediatric 
and 134 adult onset group I pulmonary arterial hypertension patients without identifiable mutations 
in known pulmonary arterial hypertension genes. Novel rare variants in the gene identified were 
independently identified in a cohort of 680 adult onset patients. Variants were expressed in COS 
cells and function assessed by patch-clamp and rubidium flux analysis. 
Results: We identified a de novo novel heterozygous predicted deleterious missense variant 
c.G2873A (p.R958H) in ABCC8 (ATP-binding cassette, subfamily C, member 8), in a child with 
idiopathic pulmonary arterial hypertension. We then examined all individuals for rare or novel 
variants in ABCC8 and identified seven additional heterozygous predicted damaging variants.  To 
replicate our findings, we examined a second cohort and identified four additional heterozygous 
predicted damaging variants in four individuals with adult-onset pulmonary arterial hypertension. 
ABCC8 encodes sulfonylurea receptor 1, a regulatory subunit of the ATP-sensitive potassium 
channel. We observed loss of function for all ABCC8 variants evaluated, and pharmacological 
rescue by the SUR1 activator, diazoxide.	
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Conclusions: Novel and rare missense variants in ABCC8 are associated with pulmonary arterial 






Pulmonary arterial hypertension is a rare and often fatal disease characterized by distinctive 
changes in pulmonary arterioles that lead to elevated pulmonary artery pressure and right sided 
heart failure. Novel treatment options have decreased mortality, but pulmonary arterial 
hypertension remains a frequently fatal illness. The heterogeneity in disease etiology and 
nonspecific patient presentation often delays diagnosis, contributing to poor outcomes.  
Genetics are recognized to play an important role in the pathogenesis of pulmonary arterial 
hypertension in patients with and without a family history of disease. Most genetic studies of the 
disease have been performed in patients with adult-onset disease. Germline mutations in bone 
morphogenetic protein receptor type 2 (BMPR2), a member of the transforming growth factor β 
(TGFβ) superfamily of receptors, have been identified as the major genetic cause, including in 
70% of inherited and 10–40% of idiopathic cases.13 Mutations in other TGFβ family members 
comprise additional rare genetic causes. The prevalence of the disease in children is estimated at 
2.2 cases per million, an order of magnitude lower than the estimated prevalence of 15-50 cases 
per million in adults,7 and there are few genetic studies of individuals with childhood-onset 
pulmonary arterial hypertension.  
We previously used exome sequencing to identify mutations in the KCNK3 potassium channel as 
a genetic cause of, and novel pharmacological target for pulmonary arterial hypertension.55 In the 
current study, we report a novel channelopathy in both pediatric and adult onset pulmonary arterial 
hypertension, functionally assess mutant channels, and characterize the pharmacological 




Genetic studies and analysis presented here were performed by Dr. Wendy Chung and 
collaborators, the methods and results of which are included in Chapter 2 of this dissertation for 
completeness. Please see Acknowledgements below for a fuller list of contributors.  
 
The study was approved by the institutional review board at Columbia University Medical Center. 
Adult cases were also enrolled to the BRIDGE-PAH (UK REC 04/Q0108/44) and to the National 
Institute for Health Research (NIHR) BioResource—Rare Diseases (UK REC 13/EE/0325)/PAH 
studies after providing informed written consent. 
 
Columbia Study Participants 
We sequenced 99 childhood onset and 134 adult onset pulmonary arterial hypertension patients 
using exome sequencing. All patients enrolled in the study carried a group I pulmonary arterial 
hypertension diagnosis, based on World Health Organization classifications; 181 idiopathic and 
52 heritable pulmonary arterial hypertension subjects were included. The diagnosis of pulmonary 
arterial hypertension was confirmed by medical record review, including right heart 
catheterization.  Heritable cases were pre-screened for BMPR2 and ACVRL1 mutations by Sanger 
sequencing and Multiplex Ligation-dependent Probe Amplification. Written informed consent and 
assent when age appropriate were obtained under a protocol approved by the institutional review 






Sample Preparation and Sequencing:  DNA was extracted from peripheral blood leukocytes 
using Puregene reagents (Gentra Systems Inc., Minnesota, USA).  Genomic DNA was prepared 
for exome capture with a custom reagent kit from Kapa Biosystems and captured with the 
NimbleGen exome design (SeqCap VCRome 2.1).  The samples were sequenced using 75 bp 
paired-end sequencing on an Illumina v4 HiSeq 2500.   
Data processing and analysis: After reads were generated by Illumina’s proprietary CASAVA 
software, sample-specific reads were aligned to the GRCh37/hg19 human genome reference 
assembly using Burrows-Wheeler Aligner (BWA).175 Once aligned, duplicate reads were marked 
with the Picard Mark Duplicates, and GATK176 was used for insertion/deletion realignment as well 
as calling SNP and insertion/deletion variants (using Haplotype Caller). Variant Quality Score 
Recalibration (VQSR) from GATK was applied to evaluate the overall quality score of a sample’s 
variants. After sample-level variant generation, and application of standard quality-control filters 
for minimum read depth (>10), genotype quality (>30), and allelic balance (>20%); passing 
variants were classified and annotated based on their potential functional effects (whether 
synonymous, missense, frameshift, or nonsense variants) and subsequently filtered by their 
observed frequencies in population control databases such as dbSNP, the 1000 Genomes 
Project,177 the NHLBI Exome Sequencing Project, the Exome Aggregation Consortium Database 
(ExAC),178 and internal databases in order to filter out common polymorphisms and high 
frequency, likely benign variants. Algorithms for bioinformatics prediction of functional effects 
of variants, such as SIFT,179 Polyphen 2,180 Meta-SVM,181 and combined annotation dependent 
depletion (CADD)182 along with conservation scores based on multiple species alignments were 
incorporated as part of the annotation process of variants and used to inform the potential 
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deleteriousness of identified candidate variants. Family relationships were analyzed using KING 
http://people.virginia.edu/~wc9c/KING/manual.html).183 
 
NIHR BioResource – Rare Diseases (BRIDGE) Study Participants 
We sequenced 680 adult onset pulmonary arterial hypertension patients using whole genome 
sequencing as part of the 10,000 genomes project. All patients enrolled in the PAH cohort had 
been diagnosed with idiopathic PAH, familial PAH and appetite drug associated PAH and written 
informed consent was obtained under a protocol approved by the UK Research Ethics Committee. 
The diagnosis of pulmonary arterial hypertension was confirmed by medical record review, 
including right heart catheterization. 
 
Whole Genome Sequencing 
Sample Preparation and Sequencing:  Genomic DNA was isolated from venous blood using 
standard techniques. Whole-genome sequencing was undertaken using the Illumina TruSeq DNA 
PCR-Free Sample Preparation kit on the Illumina HiSeq 2500 and HiSeqX platform, generating a 
minimum coverage of 15x for ~95% of the genome and an average coverage of ~30x.  
 
Data processing and analysis: Reads were aligned to the GRCh37/hg19 reference genome using 
the Isaac aligner (version 2, Illumina). SNVs, indels and SVs were identified using Illumina’s Isaac 
Variant Caller, Isaac Structural Variant Caller (Manta) and Copy Number Variant Caller (Canvas) 
[version 2]. Variants are then normalised, merged and annotated with Ensembl Variant Effect 
Predictor v84 (VEP) [doi:10.1093/bioinformatics/btq330]. Only variants that pass standard 
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Illumina quality filters in 80% of the whole BRIDGE cohort (n=8066) are taken forward for further 
analysis. 
 
In order to filter down to likely pathogenic variants the following criteria were applied: a) minor 
allele frequency is less than 1 in 10,000 in control data sets including unrelated BRIDGE-PAH 
controls (n=5668), the Exome Aggregation Consortium Database (ExAC)178 and UK10K WES 
and WGS [doi:10.1038/nature14962], b) the combined annotation dependent depletion (CADD) 
score182 is 15 or higher. Remaining variants were then manually assessed making use of other 
deleteriousness and conservation scores like SIFT,179 Polyphen 2,180 or GERP 
[doi:10.1371/journal.pcbi.1001025]. 
 
Sanger Sequence Confirmation and Segregation Analysis 
Candidate predicted pathogenic variants were confirmed by dideoxy sequencing. PCR primers 
were designed flanking approximately 250 bp of a given variant and sequenced on ABI 3730 
capillary sequencing instrument. Capillary sequence reads were analyzed using the Sequencher 
software package (GeneCodes Inc). Variants identified in heritable pulmonary arterial 
hypertension were tested in all available family members by dideoxy sequencing for segregation 
analysis. 
 
Statistical Test of Association of Rare ABCC8 Variants with PAH 
We selected 33,369 European subjects from the Exome Aggregation Consortium (ExAC) and 
49,630 Caucasian samples from Geisinger studies independently as controls for testing the genetic 
association of ABCC8 and pulmonary arterial hypertension.178 We focused on rare variants that 
	 88	
have minor allele frequency ≤0.1% estimated by ExAC.184 We used a binomial test in order to test 
the null hypothesis that the frequency of rare ABCC8 alleles in cases is the same as in controls.  We 
tested two groups of rare variants separately: (1) deleterious missense variants, defined as variants 
predicted to be damaging by Meta-SVM181 and have a CADD182 score greater than 15; and (2) 


















CU-PAH 150 6 (6) 2 (2)   
  GHS50K_ 
      EA 
49,630 165 (712) - 2.8 (0.022) - 
ExAC_NFE 33,369 148 (295) 223 (512) 4.5(0.0023) 0.87(1) 
 
 
Functional Analysis of SUR1 Activity 
We performed functional studies of SUR1, encoded by ABCC8, in association with its known 
potassium channel subunit partner, Kir6.2, encoded by KCNJ11, to form functional ATP-sensitive 
potassium (KATP) channels. Mutations were engineered into ABCC8 complementary DNA and co-
expressed along with KCNJ11 by transient transfection in COS cells. Using the whole-cell patch-
clamp technique, KATP (SUR1/Kir6.2) currents were directly measured. The application of 
diazoxide (100µM) activates KATP, while co-application of glibenclamide (10µM) inhibits KATP. 
The glibenclamide-sensitive current served as the primary quantitative measure of wildtype and 
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mutant SUR1 activity. Rubidium flux assays provided a measure of macroscopic KATP channel 
activity in intact cells in the presence and absence of diazoxide or metabolic inhibitors. 
 
Molecular Biology  
The pCMV-XL6-ABCC8 vector containing human ABCC8 cDNA encoding SUR1 protein was 
used for whole-cell electrophysiology (OriGene). A pECE-mouseKir6.2 cDNA construct was also 
used, tagged with a C-terminal GFP as a marker of cell transfection. All pulmonary arterial 
hypertension- associated mutant SUR1s were engineered by site-directed mutagenesis on the 
human ABCC8 construct using QuickChange II (Stratagene). In Rubidium flux experiments, 
pcDNA3.1-mouseKir6.2 and pECE-hamsterABCC8 cDNAs were used to optimize expression, 
with site-directed mutagenesis performed on the hamster ABCC8 cDNA construct using 
QuickChange II (Stratagene) to engineer SUR1 mutants.  
 
Whole-cell Electrophysiology 
COS-7 cells (American Type Culture Collection) were transiently transfected using Lipofectamine 
reagents (Invitrogen) and our laboratory’s established protocol.55 Co-transfection of 1.5µg SUR1 
and 0.9µg Kir6.2 cDNA was performed based on an established optimized transfection ratio for 
SUR/Kir6.2.185 COS-7 cells were cultured using 5% CO2, DMEM + GlutaMax medium (Gibco), 
10% fetal bovine serum (Gibco), and 1% Penicillin/Streptomycin (Gibco).  
 
Whole-cell KATP currents were recorded under voltage clamp conditions using an Axopatch 200B 
amplifier (Axon Instruments). A voltage ramp protocol was employed (-120mV to +60mV, 
180mV/s), applied every 3 seconds from a holding potential of -80mV, to record KATP channel 
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currents. The internal (pipette) solution (in mmol/L) was: 150 KCl, 1.2 MgCl2, 1 CaCl2, 5 EGTA, 
10 HEPES, 0.1 MgATP, at pH 7.35 using KOH. The external (bath) solution (in mmol/L) was: 
150 NaCl, 5 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES, at pH 7.4 using NaOH. 
 
For analysis, whole cell currents were normalized to cell capacitance (pA/pF), and measurements 
taken at -40mV in each cell, and in each pharmacological condition. Diazoxide (Sigma) was 
dissolved in DMSO (Life Technologies) to a 100mM stock solution, and diluted to 100µM in 
diazoxide-containing external solutions. Control external solutions (no drug) contained an 
equivalent 100µM DMSO. Glibenclamide (Sigma) was dissolved in DMSO (100mM stock 
solution) and diluted to 10µM when added to diazoxide-containing external solution. The 
glibenclamide-sensitive current (i.e. the SUR1-dependent current) was taken as the primary 
measure of SUR1 function in this assay, and these values were obtained by subtracting the current 
remaining after diazoxide+glibenclamide application (the average current amplitude 8-12 sweeps 
after the initial application of glibenclamide), from the steady state maximal current achieved by 
diazoxide. Control conditions before diazoxide application were often not at steady state due to 
dialysis of intracellular ATP; thus, control current density values were taken as an average of 4-5 
sweeps preceding diazoxide application, up to approximately 60 seconds post whole-cell break-in 
with the patch pipette as an estimate for basal channel function. Graphic analysis was performed 
using Origin 7.0 and 9.0 (Microcal Software, Northampton, MA). Data are shown as means; T 
bars indicated standard errors. Asterisks denote P<0.05 for the comparison between wildtype 
SUR1 and each mutant SUR1 or each control condition where indicated, calculated by a one-way 
ANOVA (post-hoc Tukey test). 
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Rubidium Flux Assay 
Cosm6 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) and 48 hours prior 
to testing were added to 12-well plates such that confluence reached 70-80% on the day of 
experimenting.  Individual wells were transfected 36 hours prior to testing with 0.1µg pcDNA3.1-
GFP alone (for control cells) or with 0.6µg pcDNA3.1-mouseKir6.2 and 1µg pECE-hamster 
ABCC8 using Fugene 6 (Promega). Hamster SUR1 was used for flux assays as this clone provides 
sufficiently robust expression for the flux assay. On the day of testing cells were incubated in 
DMEM media containing 1 µCi/ml 86RbCl (PerkinElmer) for > 6 hours at 37°C.  After loading 
cells were washed with Ringer’s solution containing (in mM) 118 NaCl, 10 HEPES, 25 NaHCO3, 
4.7 KCl, 1.2 KH2PO4, 2.5 CaCl2, and 1.2 MgSO4 either alone or supplemented with 2.5 mg/ml 
oligomycin and 1 mM 2-deoxy-D-glucose to induce metabolic inhibition, or 100µM diazoxide as 
indicated, and incubated at room temperature for a further 12.5 minutes. Wells were washed with 
Ringer’s solution and incubated with 800µl of Ringer’s solution with or without MI supplements 
or diazoxide (considered time point 0).  The incubating solution was collected and replaced at 
defined time points of 2.5, 5, 12.5 and 27.5 minutes.  Cells were then lysed using 2% SDS to yield 
the remaining intracellular rubidium and the radioactivity of samples was determined by 
scintillation counting.   
 
The fractional cumulative efflux at each time point was determined from the total content.   
Apparent rate constants for background, KATP-independent 86Rb+ efflux were obtained from GFP 
transfected cells using the equation: 
 
Efflux = 1 -	"#k1.% 
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where k1 represents the rate constant for background efflux.  KATP-dependent efflux was obtained 
using the equation: 
Efflux = 1 − "( -k1.% ) #*2.%)  
 
where k2 is the rate constant for efflux via the KATP-dependent pathway respectively.  The number 
of active channels is assumed to be proportional to k2.  In metabolic inhibition conditions a time-
dependent divergence from a mono-exponential efflux is observed and attributed to inactivation 
of efflux mechanisms over time, therefore in this condition rate constants were derived from 
exponential functions fit to early time points only.  Data shown represents the mean ± S.E.M. from 
at least 3 independent experiments, each with multiple replicates (N ≥ 3, n ≥ 7).  Statistical 
significance was determined using the one-way ANOVA and post-hoc Tukey test, with a p value 
< 0.05 deemed statistically significant. The Nichols lab at Washington University executed the 
rubidium flux assays.   
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to derive ABCC8 
expression patterns from healthy human lungs (controls), lungs from patients with familial 
pulmonary arterial hypertension (FPAH), and lungs from patients with pulmonary arterial 
hypertension associated with congenital heart defects (APAH). RNA and cDNA for each sample 
was prepared as previously described.157 A cDNA sample prepared as a mixture of RNA from 10 
different cell lines (Agilent) confirmed expression of ABCC8, and samples without cDNA template 
served as a negative control. The TaqMan gene expression system was used (Applied Biosystems). 
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Transcript levels were measured by the ABI Prism 7900HT Sequence Detection System (Applera). 
Applied Biosystems assays were used for priming/probing of cDNA samples, including: ABCC8 
(Hs01093774_m1) and GAPDH (Hs02758991_g1).  
 
Fold changes in gene expression, which was normalized to GAPDH expression and relative to the 
control lung samples, was calculated using the 2-ddCt method. qRT-PCR experiments were 
performed in duplicates for all samples and executed on multiple days. All data/tissue samples 




Inherited and de novo variants in ABCC8 
By exome sequencing, we identified a de novo missense variant c.G2873A (p.R958H) in ATP-
binding cassette, subfamily C, member 8 (ABCC8) (NM_001287174), which was predicted to be 
deleterious, in a patient diagnosed with idiopathic pulmonary arterial hypertension at the age of 10 
(Table 2.1). We then examined all CU-PAH patients for rare or novel variants in ABCC8 and 
identified seven additional rare damaging missense variants, predicted by multiple algorithms to 
be deleterious in seven unrelated patients with idiopathic or familial pulmonary hypertension 
(Table 2.1).  To replicate the findings in the CU-PAH cohort, we evaluated the UK-PAH cohort 
and identified three additional rare or novel missense and one splice variant in ABCC8 in three 
patients with idiopathic and one patient with congenital heart disease associated pulmonary arterial 
hypertension (Table 2.1). Five variants – c.A214G (p.N72D), c.G558T (p.E186D), c.G718A 
(p.A240T), c.G2371C (p.E791Q), and c.T2694+2G -- were novel; four rare variants – c.G331A 
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(p.G111R), c.C403G (p.L135V), c.G2437A (p.D813N), and c.G4414A (p.D1472N) -- have been 
reported in patients with congenital hyperinsulinism; and two variants – c.C686T (p.T229I) and 
c.G3941A (p.R1314H) – have been reported in patients with transient neonatal diabetes 
mellitus.186-192 Alignment of the ABCC8 sequence revealed that all missense variants occur at 
amino acid residues conserved across species and in critical domains (Figure 2.1B).	
	
All individuals were heterozygous for these rare ABCC8 variants. The L135V, D813N, and 
R1314H variants were inherited from an unaffected father, while E791Q and D1472N were 
inherited from an unaffected mother. Seven of the probands were female and five were male. None 
of the probands had any evidence of hyperinsulinism or transient/permanent neonatal diabetes 
mellitus although one adult patient had type 2 diabetes. Six of the patients were children at the 
time of diagnosis. Three patients responded and three patients did not respond to acute vasodilator 
testing using inhaled nitric oxide during cardiac catheterization. Two patients had evidence of a 
cardiac arrhythmia (Table 2.1).	
	
To estimate the genetic effect size of ABCC8 variants, we selected 33,369 European adult subjects 
from Exome Aggregation Consortium (ExAC) and 49,630 European ancestry subjects from the 
DiscovEHR study independently as controls,178 and tested for an excess of rare (minor allele 
frequency ≤0.1%) predicted deleterious missense variants in cases compared to controls. There 
were six rare predicted deleterious alleles in 150 pulmonary arterial hypertension cases of 
European ancestry in the CU-PAH cohort, while 158 unique deleterious variants were observed a 
total of 295 times in 33,369 controls with exome sequencing in the ExAC dataset and 165 rare 
unique deleterious variants were observed 721 times in the Regeneron-Geisinger DiscovEHR 
study. With binomial tests, we observed significant excess of rare predicted deleterious missense 
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variants in ABCC8 in CU-PAH cases when comparing to ExAC controls (P-value = 0.0023, 
Enrichment rate = 4.5) and to DiscovEHR controls (P-value = 0.022, Enrichment rate = 2.8). We 
tested the association of predicted benign ABCC8 variants and identified two rare synonymous 
alleles in cases, 223 unique predicted benign missense variants or synonymous variants observed 
a total of 512 times in controls, and found no significant difference between the CU-PAH group 











































ExAC_Freq N/A 0.00002 0.00003 0 0.000008 N/A 0 0.0001 0 0.00003 0 N/A 
MetaSVM_pred D D D D D D D D D D D N/A 
CADD_phred 22.8 28.4 20.5 19.46 29.4 35 32 35 27.9 23 22.4 25.1 












two affected  
siblings 
Idiopathic Idiopathic Idiopathic Idiopathic Idiopathic 
Inheritance Unknown Unknown Paternal Unknown Unknown Unknown Maternal Paternal De novo Paternal Maternal Unknown 
Gender F M M M F F F M F M F F 
Age of  
diagnosis 35 64 5 79 34 Unknown 14 12 10 <1 9 60 
RAP M (mmHg) N/A 11 9 N/A 9 N/A N/A 25 6 N/A 7 7 
PAP M (mmHg) N/A 44 55 N/A 45 N/A N/A 54 56 N/A 37 36 
AOP M (mmHg) N/A Unknown 78 N/A Unknown N/A N/A 48 88 N/A 67 Unknown 
PVRi (U*m2) N/A 19 25 N/A 13 N/A N/A 29 16 N/A 17 19 
Art Sat % N/A 97 91 N/A 98 N/A N/A 93 91 N/A 96 97 
PCWPm (mmHg) N/A 15 8 N/A 10 N/A N/A N/A 8 N/A N/A 6 
CI (L/min/m2) N/A 1.5 2.8 N/A 2.7 N/A N/A N/A 2.8 N/A 2 1.6 
Response to acute 






























None None None None 
Abbreviations: AA= amino acid, M=male, F=female, N/A=not available, RAP M=mean right atrial pressure, PAP M=mean pulmonary arterial 
pressure, AOP M=mean aortic pressure, PVRi=pulmonary vascular resistance index, Art Sat=arterial oxygen saturation, PCWPm=mean pulmonary 
capillary wedge pressure, CI=cardiac index.  UK=United Kingdom cohort, CU=Columbia University cohort. 









Figure 2.1. Topologic analysis of the SUR1 protein encoded by ABCC8, and 
sequence alignment of ABCC8 across species. Panel A shows the topology of the 
SUR1 protein. The 17 transmembrane segments are grouped into transmembrane 
domains (TMD): TMD0, TMD1, and TMD2. The two nucleotide-binding fold 
domains (NBF1 & 2) are indicated. Variants N72D, G111R, L135V, and E186D are 
located in TMD0; T229I and A240T are located in the cytoplasmic loop, L0; E791Q, 
D813N, and R958H are located in NBF1; R1314H and D1472N are located in NBF2. 
The position of each mutation is indicated by a red circle. Panel B shows the alignment 
of human ABCC8-encoding SUR1 protein with 14 different species, demonstrating 
conservation across species of each amino acid found mutated in this study.  
Human PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I I F ES P PDI DI L GLS RAM AVKR I H GGLDCA
Chimp PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I I F ES P PDI DI L GLS RAM AVKR I H GGLDCA
Hamster PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Mouse PGHNLR MPAGMA FPKLLI LLVEI N S KGTYW I KTAHR I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Rat PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Rabbit PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Pig PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Dolphin PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM XXXXXX GGLDCA
Cow PGHNLR MPAGMA FPKLLI LLVEI N S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Cat PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGLDCA
Dog PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAM AVKR I H GGL= G=
Elephant PGHNLR MPAGMA FPKLLI LLVEVN S KGTYW I KTAHK I TF ES P PDI DI L GLPRAL AVKR I H GGLDCA
Chicken PGHNLR MPAGMA FPKLLI LAVEI N S KGTYW I KTAHK I TF ES S PDI DI L NLRRPM AVKR I H GGLDCA
Fugu PGHNLR MPAALA F PKLLL LAVEI N S KATYW I TS AHR = = = = = = PDI DI L = = = = = = S VKR I N = = = = CA









Functional characterization of ABCC8 mutations 
ABCC8 encodes the sulfonylurea receptor 1 (SUR1) protein, a regulatory subunit of the KATP 
channel, which associates with the pore-forming Kir6.2 subunit.144 SUR1 controls cell excitability 
by regulating trafficking and expression of the KATP channel, and confers sensitivity of KATP 
channels to magnesium-nucleotides and pharmacological modulators. SUR1-dependent KATP 
channels are prominent in neuronal and pancreatic tissues, but present in many other tissues, 
including cardiac atria.144,193,194 We also demonstrate that ABCC8 is expressed in lungs of patients 
with pulmonary arterial hypertension and in healthy individuals (Figure 2.2), providing a potential 
target for influencing and modulating pulmonary arterial hypertension.	
	
 
Figure 2.2. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) results of 
human lung samples from patients with familial pulmonary arterial hypertension 
(FPAH), pulmonary arterial hypertension associated with congenital heart defects 
(APAH), and from healthy (Control) lungs. ABCC8 lung expression was quantified against 
an endogenous housekeeping gene, GAPDH. Panel A shows average cycle threshold (Ct) 
values at which ABCC8 appears in each condition. Panel B displays relative expression (2-ddCt) 
of ABCC8 in FPAH and APAH samples compared to Control samples. No significant 
differences in expression of ABCC8 in Control, FPAH, and APAH were observed. 
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We examined the consequence of eight of the twelve identified ABCC8 variants putatively 
associated with pulmonary arterial hypertension on SUR1 function using two complementary 
measures of KATP activity: (1) patch-clamp electrophysiology provided a direct measurement of 
whole cell KATP conductance in individual cells across different membrane potentials; and (2) 
rubidium (86Rb+) flux assays provided quantification of channel activity using 86Rb+ efflux as a 
measure of macroscopic KATP conductance from a population of intact cells.  By co-expressing 
Kir6.2 with SUR1 in COS cells, functional KATP channels were formed in each assay. All SUR1 
variants tested demonstrated loss of function in at least one functional assay. 
  
First, we used patch-clamp experiments to directly measure SUR1-dependent KATP channel 
activity by applying a voltage ramp in whole-cell conditions (Figure 2.3A), using an established 
assay.195 We maximally activated KATP channel currents with diazoxide (100µM), a selective 
SUR1 activator. Once steady-state diazoxide current activation was achieved, glibenclamide 
(10µM) – which inhibits KATP channels by binding to the SUR subunit – was co-applied. The 
glibenclamide-sensitive current was taken as the SUR1-dependent KATP current195 (Figure 2.3 and 
Figure 2.4). 
 	
Robust SUR1-dependent KATP currents were measured in cells expressing Kir6.2 and wildtype 
SUR1 (Figure 2.5A). By contrast, currents were much smaller in cells expressing A240T SUR1, 
one of the novel SUR1 variants identified, similar to currents in cells expressing D813N or 
D1472N SUR1, previously reported mutations in congenital hyperinsulinism patients (Figure 
2.5B). Further analysis demonstrated significantly reduced SUR1-dependent currents in six of 
eight SUR1 mutants evaluated, and non-significant reductions in L135V and R958H (Figure 2.5C).	
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Figure 2.3. Whole-cell patch-clamp was used to measure expressed KATP currents in response to 
pharmacological agents.  Panel A shows sample KATP channel current traces from wildtype 
SUR1+Kir6.2, activated by diazoxide 100µM (black curve) and inhibited by co-application of 
glibenclamide 10µM (red curve). A voltage ramp from -120mV to +60mV over 1 second was 
applied every 3 seconds, from a -80mV holding potential. The vertical scale is 100 pA/pF, and the 
horizontal scale is 20 mV. Panel B shows equivalent sample traces for all mutant SUR1-containing 
KATP channels. Panel C shows equivalent traces for wildtype and control conditions: (1) Kir6.2 
only; (2) SUR1 only; (3) no KATP; (4) L1016M SUR1 (identified benign variant) + Kir6.2. Panels 
D and E summarize current densities from Panels A-C, measured at -40mV (n=4 to 30 cells per 
condition). Panel F summarizes the diazoxide-activated current for wildtype and all mutant SUR1-
containing KATP channels. Data are shown as means; T bars indicate standard errors. In panel F, 
P<0.05 for the comparison of diazoxide-activated current of each KATP channel (mutant and 
























Figure 2.4. Whole-cell voltage clamp was used to measure the SUR1-dependent current of 
wildtype versus mutant KATP (SUR1/Kir6.2) channels. Panel A shows a sample glibenclamide-
sensitive current trace (SUR1-dependent current) from wildtype KATP. A voltage ramp from -
120mV to +60mV over 1 second was applied every 3 seconds, from a -80mV holding potential. 
The vertical scale is 100 pA/pF, and the horizontal scale is 20 mV. Panel B shows equivalent 
sample traces for all mutant SUR1-containing KATP channels. Panel C shows equivalent sample 
traces for wildtype and control conditions: (1) Kir6.2 only; (2) SUR1 only; (3) no KATP; (4) 
L1016M SUR1 (identified benign variant) + Kir6.2. Panels D and E summarize current densities 
from Panels A-C, measured at -40mV (n=4 to 30 cells per condition). Data are shown as means; T 
bars indicate standard errors. Asterisks denote P<0.05 for the comparison between wildtype SUR1 






























Figure 2.5. Electrophysiological consequence of SUR1 
mutations on KATP channel function. Whole-cell voltage 
clamp was used to measure expressed wildtype (WT) versus 
mutant KATP channel currents containing SUR1+Kir6.2 in 
COS7 cells. Panel A shows a wildtype SUR1-dependent 
KATP current trace. A voltage ramp from -120mV to +60mV 
over 1 second was applied every 3 seconds, from a -80mV 
holding potential. For all sample current traces, the vertical 
scale is 100 pA/pF, and the horizontal scale is 20mV. Panel 
B shows SUR1-dependent current traces of mutant KATP 
channels containing A240T, D813N, or D1472N SUR1 as 
indicated. Panel C summarizes SUR1-dependent KATP 
current densities (pA/pF) for the eight SUR1 mutants 
evaluated and wildtype, measured at -40mV (indicated by 
the black arrow in Panel A); 8 to 30 cells were studied per 
condition. Data are shown as means; T bars indicate 
standard errors. Asterisks indicate P<0.05 for the 
comparison between wildtype SUR1 and each mutant, as 
calculated by a one-way ANOVA and post-hoc Tukey test. 
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Next, 86Rb+ efflux rate was recorded as a measure of KATP channel activity in cells expressing 
wildtype or mutant SUR1 along with Kir6.2 (Figure 2.6), in basal metabolic conditions and in 
metabolic inhibition. Compared to wildtype SUR1, basal conditions yielded marked decreases in 
efflux rate for the A240T, D813N, and D1472N variants, and smaller decreases for L135V, 
E791Q, R958H, and R1314H [Figure 2.6A and 2.6B; and Table 2.2-S1]. In metabolic inhibition 
(extracellular solution supplemented with 2-deoxy-D-glucose and oligomycin to impair ATP 
synthesis and relieve KATP channels from inhibition by intracellular nucleotides), the flux rates for 
the L135V, A240T, D813N, R958H and D1472N mutants were markedly lower than wildtype 
(Figure 2.6C and 2.6D; and Table 2.2-S2). The E791Q and R1314H mutant fluxes were slightly 

















Figure 2.6. Functional impact of SUR1 mutations on macroscopic KATP channel activity.  
86Rb+ efflux was measured over time from COSm6 cells expressing KATP channels containing 
SUR1+Kir6.2. Panel A shows basal efflux for wildtype (WT, black curve) versus mutant 
(colored curves) SUR1-containing KATP channels, and GFP-alone (gray curve). Panel B 
displays the mean rate constants for KATP-dependent 86Rb+ efflux under basal conditions. Panel 
C shows efflux from cells exposed to solution containing oligomycin and 2-deoxy-D-glucose 
to induce metabolic inhibition of cells, thereby relieving KATP channels from intracellular 
inhibition by ATP. Wildtype versus mutant SUR1-containing KATP channels, and GFP-alone, 
are compared. The inset shows exponential fits to early time points which were used to derive 
the efflux rate constants (see Supplementary Appendix). Panel D shows the mean rate constants 
for KATP-dependent 86Rb+ efflux under metabolic inhibition conditions. For each condition, 7 
to 10 cell populations were studied. Data are shown as means; T bars indicate standard errors. 
Asterisks indicate P<0.05 for the comparison between wildtype SUR1 and each mutant, as 
calculated by a one-way ANOVA and post-hoc Tukey test.  
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Table 2.2. Sub-tables S1-S3 show rate constants derived from rubidium flux experiments 












Thus, there was a decrease in basal and/or maximal channel activity for all SUR1 mutants 
associated with pulmonary arterial hypertension tested in our study. As discussed below, such loss 
of function could result from various mechanisms, but any channel activity present might be 
augmented by selective potassium channel opening drugs, such as diazoxide. Consistent with this 
suggestion, all mutants tested were pharmacologically activated by diazoxide (100µM) in 
rubidium efflux (Figure 2.7A and 2.7B; and Table 2.2-S3), and electrophysiological assays (Figure 




















Figure 2.7. Pharmacological recovery of mutant KATP channels. Diazoxide restores function 
of KATP channels (SUR1/Kir6.2) containing mutant SUR1. Panel A shows rubidium efflux in 
the presence of diazoxide 100µM for wildtype (WT) SUR1 (black curve), mutant SUR1-
containing KATP channels (colored curves), and GFP-alone (gray curve). Panel B shows average 
efflux rates for wildtype and mutant KATP channels in basal (gray) versus diazoxide 100µM 
(black) conditions. For each condition, 7 to 10 cell populations were studied. Panel C depicts 
whole-cell drug time courses of wildtype and selected mutant KATP channel currents before 
drug application (gray, control), during diazoxide 100µM application (black), and during co-
application of glibenclamide 10µM with diazoxide 100µM (red). The vertical scale is 25 pA/pF, 
and the horizontal scale is 1 minute. Arrows indicate the maximal steady-state current-density 
(pA/pF) achieved during diazoxide 100µM application. Panel D summarizes current density 
(pA/pF at -40mV) for wildtype and each mutant SUR1-containing KATP channel, in control 
(gray) and diazoxide 100µM (black) conditions; 6 to 30 cells were studied per condition. Data 
are shown as means; T bars indicate standard errors. Asterisks denote P<0.05 for the 
comparison of basal and diazoxide (Panel B), or control and diazoxide (Panel D), calculated by 




Using exome sequencing, we identified de novo and inherited heterozygous mutations in a novel 
candidate gene, ABCC8, potentially associated with familial and idiopathic pulmonary arterial 
hypertension, in eight independent families, with six of the probands diagnosed as children in the 
CU-PAH study. We identified an additional four rare or novel predicted damaging missense and 
splice variants in ABCC8 in a second cohort (UK-PAH) of adult group I pulmonary arterial 
hypertension patients with idiopathic, familial or appetite drug-associated disease. Functional 
analyses demonstrated reduced ATP-sensitive potassium (KATP) channel activity in all SUR1 
mutants tested and pharmacological rescue of KATP activity by diazoxide. Our results suggest a 
role for ABCC8 in the pathogenesis of pulmonary arterial hypertension, and as a potential 
therapeutic target. 	
 	
ABCC8 encodes the sulfonylurea receptor 1 (SUR1) protein, a KATP channel subunit. The eleven 
identified missense ABCC8 variants are all rare, located at residues highly conserved across 
species, and reside in intracellular and transmembrane domains of SUR1, including nucleotide 
binding fold regions (Figure 2.1). ABCC8 is highly expressed in the human brain and endocrine 
pancreas, and moderately expressed in human lungs196 (Figure 2.2). In pancreatic β-cells, high 
intracellular ATP concentrations (eg. during post-prandial glucose metabolism) close the channel, 
causing cell depolarization, activation of voltage-gated calcium channels, leading to insulin 
secretion.193 	
	
KATP channel activity contributes to cell excitability in multiple other tissues,144 including cardiac 
atrium.194 It has been reported that SUR2B is the predominant SUR isoform expressed in cultured 
pulmonary artery smooth muscle cells,126 but the details of subunit composition of KATP channels 
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in native pulmonary artery smooth muscle and endothelial cells in different conditions remains 
unclear. There is evidence for KATP channels in pulmonary artery smooth muscle and endothelial 
cells and SUR1 expression in pulmonary arteries,126,197 while KATP channel activity is upregulated 
by elevated shear stress in pulmonary vascular endothelial cells.197 More recently, SUR1 
upregulation by hypoxia was reported in cerebral microvascular endothelial cells.198,199 KCNK3, 
established as the first potassium channelopathy in pulmonary arterial hypertension,55,75 is also 
regulated by hypoxia in pulmonary artery smooth muscle cells, and may contribute to hypoxic 
pulmonary vasoconstriction.73  
 
SUR1-dependent KATP channel loss of function alongside KCNK3 channel loss of function 
therefore represent possible pathogenic mechanisms in pulmonary arterial hypertension, and 
pharmacologic recovery of channel function a therapeutic avenue.55,75 Complementary and 
redundant potassium channel activity could contribute to the lung-specific phenotype observed 
clinically in patients with heterozygous ABCC8 or KCNK3 mutation.1,89 
  
All ABCC8 variants that we identified and functionally assessed represent loss of function 
mutations. The disease consequences may vary, as there is clearly incomplete penetrance within 
our families with several asymptomatic transmitting parents. Dominant and recessively inherited 
mutations in ABCC8 cause neonatal/adult-onset diabetes or congenital hyperinsulinism, due to 
gain or loss of ABCC8 function, respectively.191,200 Dominantly inherited ABCC8 mutations 
affecting glucose homeostasis display incomplete penetrance, and patients with only one ABCC8 
mutation often have milder or no disease.   
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Despite loss of ABCC8 function underlying many cases of congenital hyperinsulinism, the patients 
in our study have no evidence of hyperinsulinemic hypoglycemia or transient/permanent neonatal 
diabetes mellitus. This raises the question: why do SUR1-dependent pulmonary arterial 
hypertension patients not have hyperinsulinism, and vice versa, why do hyperinsulinism patients 
not have evidence of pulmonary arterial hypertension? The L135V and D1472N ABCC8 variants 
we identified have been reported as recessive alleles in congenital hyperinsulinism,186,192,201-203 
while D813N and D1472N have been reported as variants in autosomal dominant or recessive 
congenital hyperinsulinism inherited from unaffected fathers,187,188 with loss of heterozygosity 
observed for D1472N.204	
 	
Imprinting at the 11p15 chromosomal region near the ABCC8 gene locus can lead to pancreatic 
endocrine cell proliferation in focal hyperinsulinemic patients possessing loss of function ABCC8 
mutations.205 Tissue-specific consequences of imprinting near the ABCC8 gene locus and/or 
somatic loss of ABCC8 in the pulmonary vasculature could predispose to lung specific disease in 
the setting of germline ABCC8 loss of function mutations. A combination of genetic, 
developmental, and environmental factors may determine which patients with ABCC8 mutations 
develop pulmonary arterial hypertension. 	
	
The mechanism of SUR1 loss of function likely varies based on mutation location with the channel 
subunit. For instance, G111R and D1472N have been previously shown to decrease SUR1 
trafficking to the plasma membrane,187,192,202 while nucleotide binding fold mutations, D813N and 
R958H, may impair magnesium-nucleotide activation. SUR1 mutation severity impacts viability 
for pharmacological rescue, as previously demonstrated for KCNK3 mutant channels associated 
with pulmonary arterial hypertension,55 and for SUR1 mutants associated with congenital 
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hyperinsulinism.206 We observed variable functional recovery by diazoxide of each SUR1 mutant 
tested. Diazoxide is a SUR1 activator clinically employed as an anti-hypertensive and anti-
hyperinsulinism agent. Case reports have already described the successful use of diazoxide to 
reverse pulmonary hypertension,207,208 underscoring SUR1-dependent KATP activation as an 
intriguing potential basis for pulmonary hypertension therapy.209 	
	
As mainstay treatment in congenital hyperinsulinism, diazoxide administration overcomes 
disease-causing ABCC8 loss-of-function mutations. Rarely, diazoxide administration to 
hypoglycemic neonates has been associated with pulmonary arterial hypertension;210 however, this 
may be secondary to inadequate diuresis with diazoxide treatment, leading to volume overload 
following systemic blood volume expansion. Ultimately, KATP channel activators with less 
pulmonary toxicity may prove more useful for pulmonary hypertension treatment.211  
 
In conclusion, we have identified mutations in the ABCC8 gene as a second potassium 








Pulmonary arterial hypertension (PAH) is a devastating illness with significant morbidity and high 
mortality rates. Newer medical treatments have improved clinical outcomes, yet patient prognosis 
remains poor. Research into disease pathogenesis aims to uncover pathological processes in 
pulmonary arterioles that may offer novel treatment targets. My thesis work focuses on potassium 
channel dysfunction as a cause of PAH, and recovery of potassium channel currents as a potential 
therapeutic avenue.  
 
Our research group had identified loss-of-function KCNK3 mutations as a cause of pulmonary 
arterial hypertension in patients heterozygous at the KCNK3 gene locus. Furthermore, a KCNK3-
activator (ONO-RS-082) was shown to recover function of some mutant KCNK3 channels. In the 
research presented here, we have expanded upon the original characterization of mutant channel 
dysfunction, to uncover mechanisms of KCNK3 dysfunction and characterize channel function 
and recovery in more physiological relevant heterozygous conditions.  
 
KCNK3 is an acid-sensitive, two-pore domain potassium channel. We determined that the V221L 
KCNK3 mutation confers a pH-dependent mechanism of loss-of-function, while the G203D 
mutation confers a more severe loss-of-function phenotype. Mature KCNK3 channels function as 
dimers, composed of two KCNK3 subunits that co-assemble. We engineered tandem-linked 
heterodimeric mutant KCNK3 channels containing one mutant and one non-mutant KCNK3 
subunit in order to study the impact of heterozygosity on channel function, and observed 
intermediate function of mutant WT-V221L KCNK3 heterodimeric compared to WT and V221L 
homodimeric channels. Thus, the engineered heterodimers reported function of a substantial, 
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discrete proportion of formed channels in heterozygous conditions. Moreover, we observed 
pharmacological activation of the mutant heterodimers by ONO-RS-082. When examining V221L 
KCNK3 channel function in cultured pulmonary artery smooth muscle cells expressing the mutant 
channels, we observed pharmacological recovery of mutant KCNK3 function as measured by 
membrane hyperpolarization. Together, we concluded that mutant KCNK3 channels can be 
pharmacologically targeted for activation in heterozygous KCNK3 conditions. 
 
To understand why heterozygous mutations in KCNK3 leads to PAH, but no other medical illness, 
despite widespread tissue expression of KCNK3, we turned to experiments with the closely related 
KCNK9 channel. We observed that KCNK3 is expressed in healthy and PAH patient lungs, while 
KCNK9 is not appreciably expressed. KCNK3 and KCNK9 channels have been shown to be co-
expressed in other tissues, such as in the central nervous system, and were shown to co-assemble 
to form KCNK9-KCNK3 heterodimeric channels. With this in mind, we tested the hypothesis that 
KCNK9, an acid-sensitive channel that is more maximally activated at physiological pH 7.4, could 
recover function of mutant KCNK3, which may provide protection against KCNK3 dysfunction 
in tissues where both KCNK3 and KCNK9 are co-expressed. Indeed, we observed that KCNK9 
heterodimerizes with KCNK3 to produce robust currents at physiological pH 7.4, and the assembly 
of KCNK9 with the severe mutant G203D KCNK3 channel recovers some channel function. 
Therefore, KCNK9-KCNK3 heterodimerization outside of the lung may contribute to the lung-
specific phenotype seen in patients with heterozygous KCNK3 mutation. 
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In chapter 2, we have reported that loss of function mutations in ABCC8 are associated with 
pulmonary arterial hypertension in pediatric and adult patients. The genetic association of ABCC8 
in PAH was independently replicated in a second, separate patient cohort. 
 
ABCC8 encodes the sulfonylurea receptor 1 (SUR1) protein, a beta subunit of the ATP-sensitive 
potassium (KATP) channel. Using whole-cell voltage clamp electrophysiology and rubidium flux 
assays, we tested function of SUR1 mutants assembled with the pore- forming Kir6.2 alpha subunit 
of the KATP channel. Functional assessment revealed loss of function of all SUR1 mutants studied, 
in at least one functional assay, and recovery of function of all mutant SUR1-containing KATP 
channels upon application of the KATP channel opener (and SUR1 activator), diazoxide. Therefore, 
SUR1 dysfunction represents a potential pathogenic mechanism in PAH and therapeutic target. 
 
Thus, we have characterized two potassium channelopathies, in the KCNK3 and ABCC8 genes, 
associated with pulmonary arterial hypertension. In future studies, employing animal models of 
PAH may prove fruitful in order to investigate the pathophysiological consequences of potassium 
channel dysfunction. To model heterozygous KCNK3 and ABCC8 mutation and the consequences 
for pulmonary arteries, CRISPR knock-in technology may also be employed to study select 
mutations (eg. V221L KCNK3) in heterozygous conditions.212 Evidence of pulmonary dysfunction 
at the pulmonary arterial level, combined with therapeutic relief of pulmonary arterial pressure by 
potassium channel opening drugs, may bring the scientific field closer to translating our genetic 
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